ABVC BioPharma (ABVC) 10-K 16 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 15, 2021	Jun. 30, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	American BriVision (Holding) Corp
Entity Central Index Key	0001173313
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Filer Number	333-91436
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NV
Entity Common Stock, Shares Outstanding		24,420,526
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Public Float			$ 73,261,578

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 4,273,208	$ 144,295
Restricted cash and cash equivalents	728,163	16,148
Accounts receivable, net	159,712	163,566
Accounts receivable - related parties, net	143,435	143,278
Due from related parties	696,255	333,682
Inventory, net
Prepaid expense and other current assets	172,193	77,269
Total Current Assets	6,172,966	878,238
Property and equipment, net	514,834	520,930
Operating lease right-of-use assets	1,772,747	524,445
Goodwill, net
Long-term investments	1,190,727	3,364,619
Deferred tax assets	1,790,597	1,460,033
Prepaid expenses - noncurrent	119,315	135,443
Security deposits	45,519	44,103
Total Assets	11,606,705	6,927,811
Current Liabilities
Accounts payable	23,044	23,995
Short-term bank loans	1,629,000	1,918,500
Short-term loan	100,000
Long-term bank loans  - current portion		13,403
Notes payable	106,800	100,200
Accrued expenses and other current liabilities	2,118,854	2,007,573
Advance from customers	12,070	13,085
Operating lease liabilities - current portion	316,178	304,248
Due to related parties	288,445	425,689
Convertible notes payable - current portion		820,000
Convertible notes payable - related parties, current portion	250,000	1,187,500
Total Current Liabilities	4,844,391	6,814,193
Paycheck Protection Program Loan Payable	124,400
Tenant security deposit	19,280	2,880
Operating lease liability - noncurrent portion	1,456,567	235,555
Convertible notes payable – noncurrent portion	2,500,000
Total Liabilities	8,944,638	7,052,628
Equity
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 authorized, 24,420,526 and 19,478,168 shares issued and outstanding	24,420	19,478
Additional paid-in capital	40,751,807	28,180,348
Stock subscription receivable	(3,160,360)	(4,063,320)
Accumulated deficit	(25,642,387)	(15,851,223)
Accumulated other comprehensive income	564,860	663,753
Treasury stock	(9,100,000)	(9,100,000)
Total Stockholders' deficit	3,438,340	(150,964)
Noncontrolling interest	(776,273)	26,147
Total Equity (Deficit)	2,662,067	(124,817)
Total Liabilities and Equity (Deficit)	$ 11,606,705	$ 6,927,811

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	24,420,526	19,478,168
Common stock, shares outstanding	24,420,526	19,478,168

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues	$ 483,045	$ 701,719
Cost of revenues	18,716	20,137
Gross profit	464,329	681,582
Operating expenses
Selling, general and administrative expenses	4,273,468	3,069,493
Research and development expenses	549,658	1,048,553
Stock based compensation	4,146,979	22,314
Total operating expenses	8,970,105	4,140,360
Loss from operations	(8,505,776)	(3,458,778)
Other income (expense)
Interest income	71,045	23,344
Interest expense	(405,032)	(482,014)
Rent income	20,071	19,487
Rent income - related parties	4,800	4,400
Impairment loss	(961,217)
Investment loss	(40,589)
Gain/Loss on foreign exchange changes	(3,275)	407
Gain/Loss on investment in equity securities	(1,168,733)	(210,086)
Other income	174,770	92,959
Total other expenses	(2,308,160)	(551,503)
Loss before provision income tax	(10,813,936)	(4,010,281)
Provision for income tax	(220,352)	(77,041)
Net loss	(10,593,584)	(3,933,240)
Net loss attributable to noncontrolling interests	(802,420)	(291,464)
Net loss attributed to ABVC and subsidiaries	(9,791,164)	(3,641,776)
Foreign currency translation adjustment	(98,893)	7,902
Comprehensive loss	$ (9,890,057)	$ (3,633,874)
Net loss per share:
Basic and diluted	$ (0.5)	$ (0.21)
Weighted average number of common shares outstanding:
Basic and diluted	19,715,559	17,498,543

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (10,593,584)	$ (3,933,240)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	37,142	55,086
Stock based compensation	4,146,979	22,314
Gain/Loss on investment in equity securities	1,168,733	210,086
Other non-cash income and expenses	(15,360)	(5,747)
Investment loss	1,001,806
Deferred tax	(223,201)	(80,692)
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	3,696	(120,739)
Decrease (increase) in prepaid expenses and deposits	(15,778)	(27,617)
Decrease (increase) in due from related parties	(1,190,755)	(282,092)
Decrease (increase) in inventory		1,306
Increase (decrease) in accounts payable	(951)	50,244
Increase (decrease) in notes payable		(4,861)
Increase (decrease) in accrued expenses and other current liabilities	(359,822)	801,434
Increase (decrease) in advanced from others	(1,015)	1,909
Increase (decrease) in due to related parties	501,457	178,083
Net cash used in operating activities	(5,540,653)	(3,134,526)
Cash flows from investing activities
Net proceeds from sale of investment	147,804
Loan to related parties	603,499	(17,496)
Long-term equity investment		(17,801)
Net cash used in investing activities	751,303	(35,297)
Cash flows from financing activities
Issuance of common stock for cash	7,615,331
Issuance of common shares for stock-based compensation		552,962
Proceeds from issuance of common stock for acquisition		531,147
Proceeds from convertible notes	2,500,000	1,207,500
Proceeds from short-term bank loan and third parties	650,000
Proceeds from short-term loan	100,000	1,000,000
Proceeds from long-term loan	124,400
Net (repayments of) proceeds from short term borrowings from third parties	(408,285)	657,466
Repayment of borrowings from related parties		(820,000)
Repayment of long-term bank loans	(1,013,603)	(41,586)
Net cash provided by financing activities	9,567,843	3,087,489
Effect of exchange rate changes on cash and cash equivalents and restricted cash	62,435	(4)
Net increase (decrease) in cash and cash equivalents and restricted cash	4,840,928	(82,338)
Cash and cash equivalents and restricted cash
Beginning	160,443	242,781
Ending	5,001,371	160,443
Cash paid during the year for:
Interest expense paid	208,556	167,126
Income taxes paid		2,050
Non-cash financing and investing activities
Common shares issued for employees and consultants		325,740
Capital contribution from related parties under common control		$ 7,872,340

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Stock Subscription Receivable	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Treasury Stock	Noncontrolling Interest	Total
Balance at Dec. 31, 2018	$ 11,885		$ 14,983,714	$ (12,209,446)	$ 655,851	$ (9,100,000)	$ 317,610	$ (5,340,386)
Balance, shares at Dec. 31, 2018	11,884,804					(275,347)
Issuance of common shares	$ 7,593	(4,063,360)	13,174,320					9,118,593
Issuance of common shares, shares	7,593,364
Stock based compensation			22,314					22,314
Net loss for the year				(3,641,777)			(291,463)	(3,933,240)
Cumulative transaction adjustments					7,902			7,902
Balance at Dec. 31, 2019	$ 19,478	(4,063,320)	28,180,348	(15,851,223)	663,753	$ (9,100,000)	26,147	(124,817)
Balance, shares at Dec. 31, 2019	19,478,168					(275,347)
Capital contribution	$ 3,385		7,611,946					7,615,331
Capital contribution, shares	3,384,615
Stock based compensation for options granted			1,706,419					1,706,419
Stock based compensation for services	$ 642	902,960	1,536,958					2,440,560
Stock based compensation for services, shares	641,887
Debt conversion	$ 915		1,716,136					1,717,051
Debt conversion, shares	915,856
Net loss for the year				(9,791,164)			(802,420)	(10,593,584)
Cumulative transaction adjustments					(98,893)			(98,893)
Balance at Dec. 31, 2020	$ 24,420	$ (3,160,360)	$ 40,751,807	$ (25,642,387)	$ 564,860	$ (9,100,000)	$ (776,273)	$ 2,662,067
Balance, shares at Dec. 31, 2020	24,420,526					(275,347)

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	1. ORGANIZATION AND DESCRIPTION OF BUSINESS American BriVision (Holding) Corporation (the "Company" or "Holding entity"), a Nevada corporation, through the Company's operating entity, American BriVision Corporation ("BriVision"), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical trials for the Company's drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering Cancer Center ("MSKCC") and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July 21, 2015. Reverse Merger On February 8, 2016, a Share Exchange Agreement (the "Share Exchange Agreement") was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation ("BriVision"), and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China ("Euro-Asia"), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the "BriVision Stock"). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 166,273,921(52,936,583 pre-stock split) shares (the "Acquisition Stock") (subject to adjustment for fractionalized shares as set forth below) of the Company's Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company's Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the "Merger"). Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company's Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company's Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the "Share Exchange"), BriVision had become a wholly owned subsidiary (the "Subsidiary") of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. Upon the consummation of the Share Exchange, BriVision became a wholly owned subsidiary of the Company. Following the Share Exchange, the Company has abandoned prior business plan and is now pursuing BriVision's historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept ("POC"), out-license to international pharmaceutical companies, and explore global markets. Accounting Treatment of the Reverse Merger For financial reporting purposes, the Share Exchange represents a "reverse merger" rather than a business combination and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange. Merger On February 8, 2019, the Company, BioLite Holding, Inc. ("BioLite"), BioKey, Inc. ("BioKey"), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent ("Merger Sub 1"), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent ("Merger Sub 2") (collectively referred to as the "Parties") completed the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the shareholders of BioLite and BioKey. Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares (prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285), which became effective by operation of law on or about February 5, 2019. BioLite Holding, Inc. (the "BioLite Holding") was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the "BioLite BVI"), a wholly owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are holding companies and have not carried out substantive business operations of their own. BioLite, Inc., (the "BioLite Taiwan") was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom. In January 2017, BioLite Holding, BioLite BVI, BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the "BioLite Share Purchase / Exchange Agreement"). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan. BioKey, Inc. was incorporated on August 9, 2000 in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development processes with other biotechnology, pharmaceutical, and nutraceutical companies. Accounting Treatment of the Merger The Company adopted ASC 805, "Business Combination" to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang's common control, the transaction is accounted for as a restructuring transaction. All the assets and liabilities of BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding's common shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the earnings (or losses) of the transferred net assets.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the "U.S. GAAP"). All significant intercompany transactions and account balances have been eliminated. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company's financial statements are expressed in U.S. dollars. Fiscal Year The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results. Inventory Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence. Reclassifications Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit. Forward Stock Split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. Stock Reverse Split On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized common stock of the Company (the "Common Stock") and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split. Fair Value Measurements FASB ASC 820, "Fair Value Measurements" defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows: ● Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available. ● Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability. The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company's short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company's long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities. Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2020 and December 31, 2019, the Company's cash and cash equivalents amounted 4,273,208 and $144,295, respectively. Some of the Company's cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality. Restricted Cash Equivalents Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of December 31, 2020 and December 31, 2019, the Company's restricted cash equivalents amounted $728,163 and $16,148, respectively. Concentration of Credit Risk The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation's insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Revenue Recognition During the fiscal year 2018, the Company adopted Accounting Standards Codification ("ASC"), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company's reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company's review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company's revenue during all periods presented. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The following are examples of when the Company recognizes revenue based on the types of payments the Company receives. Collaborative Revenues — As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&D personnel costs, discount rates and probabilities of technical and regulatory success. The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company's deliverables requires the use of management's judgment. Significant factors considered in management's evaluation of the estimated performance periods include, but are not limited to, the Company's experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition. (i) Non-refundable upfront payments If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements. (ii) Milestone payments The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company's obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company's obligations under the collaborative agreement with collaboration partners. The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs. (iii) Multiple Element Arrangements The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s). The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company's contractual or estimated performance period for the undelivered elements, which is typically the term of the Company's research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date. At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company's performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met. (iv) Royalties and Profit Sharing Payments Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved. Revenues Derived from Research and Development Activities Services — Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation. If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations. The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company's transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price. The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less. Property and Equipment Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives: Estimated Life Buildings and leasehold improvements 5 ~ 50 Machinery and equipment 5 ~ 10 Office equipment 3 ~ 6 Impairment of Long-Lived Assets The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment ("ASC 360-10"). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. Long-term Equity Investment The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as: ● Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments. ● Non-marketable cost method investments when the equity method does not apply. Significant judgment is required to identify whether an impairment exists in the valuation of the Company's non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee's industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees' revenue, costs, and discount rates. The Company's assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions. Other-Than-Temporary Impairment The Company's long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows: ● Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee's credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments. ● Non-marketable equity investments based on the Company's assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee's ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $961,217 and $0 for the year ended December 31, 2020 and 2019, respectively. Goodwill The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions. The Company completed the required testing of goodwill for impairment as of December 31, 2020, and determined that goodwill was impaired because of the current financial condition of the Company and the Company's inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured. Research and Development Expenses The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred. For CDMO business unit, the Company accounts for R&D costs in accordance with Accounting Standards Codification ("ASC") 730, Research and Development ("ASC 730"). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed. Post-retirement and post-employment benefits The Company's subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the "Act") in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker's monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees' salaries to the employees' pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $13,961and $15,928 for the year ended December 31, 2020 and 2019, respectively. Other than the above, the Company does not provide any other post-retirement or post-empl

Collaborative Agreements

Collaborative Agreements	12 Months Ended
	Dec. 31, 2020
Collaborative Agreements [Abstract]
COLLABORATIVE AGREEMENTS	3. COLLABORATIVE AGREEMENTS Collaborative agreements with BHK (i) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the "BHK") entered into a co-development agreement, (the "BHK Co-Development Agreement"), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan. On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule: ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment In December 2015, BHK has paid a non-refundable upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical trial. In addition to the milestone payments, BioLite Taiwan is entitled to receive royalty on 12% of BHK's net sales related to BLI-1401-2 Products. As of December 31, 2020 and 2019, the Company has not earned the royalty under the BHK Co-Development Agreement. (ii) On December 9, 2015, BioLite Taiwan entered into another two collaborative agreements (the "BHK Collaborative Agreements"), pursuant to which it is collaborative with BHK to co-develop and commercialize BLI-1005 for "Targeting Major Depressive Disorder" (BLI-1005 Products) and BLI-1006 for "Targeting Inflammatory Bowel Disease" (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan. In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this BHK Collaborative Agreements. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of December 31, 2020 and 2019, the Company has not earned the royalty under the BHK Collaborative Agreements. Co-Development agreement with Rgene Corporation, a related party On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the "Co-Dev Agreement") with Rgene Corporation (the "Rgene"), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision's past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both BriVision and Rgene. On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene's Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully write off this investment based on the Company's assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene's ability to remain in business. All projects that have been initiated will be managed and supported by the Company and Rgene. The Company and Rgene signed an amendment to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions of the Co-Dev Agreement remain in full force and effect. Collaborative agreement with BioFirst Corporation, a related party On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the "BioFirst Collaborative Agreement") with BioFirst Corporation ("BioFirst"), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the "Product"): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See Note 12). Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before December 31, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst's past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst. On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended December 31, 2017. On June 30, 2019, BriVision entered into a Stock Purchase Agreement (the "Purchase Agreement") with BioFirst Corporation ("BioFirst"). Pursuant to the Purchase Agreement, the Company issued 428,571 shares of the Company's common stock (the "Shares") to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst (the "Total Payment") in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the "Collaborative Agreement"). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment. On August 5, 2019, BriVision entered into a second Stock Purchase Agreement ("Purchase Agreement 2") with BioFirst Corporation ("BioFirst"). Pursuant to Purchase Agreement 2, the Company issued 414,702 shares of the Company's common stock (the "Shares") to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst (the "Total Payment") in connection with a loan provided to BriVision from BioFirst.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
INVENTORY	4. INVENTORY Inventory consists of the following: December 31, December 31, Finished goods $ 100,967 $ 94,727 Work-in-process 22,038 20,676 Raw materials 61,718 57,904 Allowance for inventory valuation and obsolescence loss (184,723 ) (173,307 ) Inventory, net $ - $ -

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	5. PROPERTY AND EQUIPMENT Property and equipment as of December 31, 2020 and 2019 are summarized as follows: December 31, December 31, Land $ 395,645 $ 371,195 Buildings and leasehold improvements 2,233,573 2,225,386 Machinery and equipment 994,544 987,234 Office equipment 189,760 178,409 3,813,522 3,762,224 Less: accumulated depreciation (3,298,688 ) (3,241,294 ) Property and equipment, net $ 514,834 $ 520,930 Depreciation expense were $37,142 and $55,086 for the year ended December 31, 2020 and 2019, respectively.

Long-Term Investments

Long-Term Investments	12 Months Ended
	Dec. 31, 2020
Long-Term Investment [Abstract]
LONG-TERM INVESTMENTS	6. LONG-TERM INVESTMENTS (1) The ownership percentages of each investee are listed as follows: Ownership percentage December 31, December 31, Accounting Name of related party 2020 2019 treatments Braingenesis Biotechnology Co., Ltd. 0.17 % 0.17 % Cost Method Genepharm Biotech Corporation 0.70 % 0.72 % Cost Method BioHopeKing Corporation 5.90 % 7.13 % Cost Method BioFirst Corporation 15.99 % 15.89 % Equity Method Rgene Corporation 31.62 % 31.61 % Equity Method (2) The extent the investee relies on the company for its business are summarized as follows: Name of related party The extent the investee relies on the Company for its business Braingenesis Biotechnology Co., Ltd. No specific business relationship Genepharm Biotech Corporation No specific business relationship BioHopeKing Corporation Collaborating with the Company to develop and commercialize drugs BioFirst Corporation Loaned from the investee and provides research and development support service Rgene Corporation Collaborating with the Company to develop and commercialize drugs (3) Long-term investment mainly consists of the following: December 31, December 31, Non-marketable Cost Method Investments, net Braingenesis Biotechnology Co., Ltd. $ 7,853 $ 7,367 Genepharm Biotech Corporation 23,974 22,493 BioHopeKing Corporation 890,564 1,998,310 Sub total 922,391 2,028,170 Equity Method Investments, net BioFirst Corporation 268,336 1,336,449 Rgene Corporation - - Total $ 1,190,727 $ 3,364,619 (a) BioFirst Corporation (the "BioFirst"): The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures ("ASC 323"). Equity method adjustments include the Company's proportionate share of investee's income or loss and other adjustments required by the equity method. As of December 31, 2020 and 2019, the Company owns 15.99% and 15.89% common stock shares of BioFirst, respectively. Summarized financial information for the Company's equity method investee, BioFirst, is as follows: Balance Sheet December 31, December 31, Current Assets $ 1,299,822 $ 1,350,701 Noncurrent Assets 2,540,041 7,450,032 Current Liabilities 1,986,340 2,060,460 Noncurrent Liabilities 73,197 78,888 Stockholders' Equity 1,780,326 6,661,385 Statement of operation Year Ended 2020 2019 Net sales $ 257,235 $ 43,975 Gross profit 10,121 (37,160 ) Net loss (5,401,074 ) (972,303 ) Share of losses from investments accounted for using the equity method (1,168,733 ) (210,086 ) (b) Rgene Corporation (the "Rgene") Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures ("ASC 323"). Equity method adjustments include the Company's proportionate share of investee's income or loss and other adjustments required by the equity method. As of December 31, 2020 and 2019, the Company owns 31.62% and 31.61% common stock shares of Rgene, respectively. Summarized financial information for the Company's equity method investee, Rgene, is as follows: Balance Sheets December 31, December 31, Current Assets $ 123,958 $ 82,254 Noncurrent Assets 412,342 62,768 Current Liabilities 1,392,756 312,950 Noncurrent Liabilities 38,953 - Shareholders' Deficit (895,409 ) (167,928 ) Statement of operations Year Ended 2020 2019 Net sales $ 16,595 $ - Gross Profit (335,735 ) - Net loss (641,636 ) (53,877 ) Share of loss from investments accounted for using the equity method - - (4) Disposition of long-term investment During the year ended December 31, 2020, the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the same period. (5) Losses on Equity Investments The components of losses on equity investments for each period were as follows: Year Ended 2020 2019 Share of equity method investee losses $ (1,168,733 ) $ (210,086 )

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2020
Convertible Notes Payable [Abstract]
CONVERTIBLE NOTES PAYABLE	7. CONVERTIBLE NOTES PAYABLE On May 9, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the "Yu and Wei Note") in an aggregate principal amount of $300,000 to Guoliang Yu and Yingfei Wei Family Trust (the "Yu and Wei"), pursuant to which the Company received $300,000. The Yu and Wei Note bears interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Yu and Wei" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Yu and Wei". The aggregate principal amount plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company's common stock, and warrants to purchase 192,784 shares of the Company's common stock. As of December 31, 2020, these common shares have been issued. On June 27, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the "Keypoint Note") in the aggregate principal amount of $250,000 to Keypoint Technology Ltd. ("Keypoint"), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Keypoint" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Keypoint". The aggregate principal amount plus accrued interest expenses were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company's common stock, and warrants to purchase 159,145 shares of the Company's common stock. As of December 31, 2020, these common shares have been issued. On August 25, 2018, the Company issued an eighteen-month term unsecured convertible promissory notes (the "Odaira Note") in the aggregate principal amount of $250,000 to Yoshinobu Odaira. ("Odaira"), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21, 2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Odaira" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Odaira". The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company's common stock, and warrants to purchase 154,368 shares of the Company's common stock. As of December 31, 2020, these common shares have been issued. On May 30 and July 10, 2019, the Company issued two (2) twelve-month term unsecured convertible promissory notes (the "KSL Note") in an aggregate principal amount of $250,000 to Kuo Sheng Lung (the "KSL"), pursuant to which the Company received $160,000 and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020. At any time from the issuance date until the KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $0.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company entered into an agreement with "KSL". The aggregate principal amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company's common stock and warrants for a purchase price of $270,272. As of December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company's common stock. On July 10, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the "NEA Note") in an aggregate principal amount of $250,000 to New Eastern Asia (the "NEA"), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note. As of December 31, 2020, the Company paid off the convertible promissory note of $306,667, including principal and accrued and unpaid interest expense. On August 28, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the "KLS Note") in an aggregate principal amount of $200,000 to Kuo Li Shen (the "KLS"), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum. The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company's common stock, and warrants to purchase 126,530 shares of common stock. As of December 31, 2020, these common shares have been issued. On September 4, 2019, the Company issued 3 twelve-month term unsecured convertible promissory note (the "C.L.L. Note") in an aggregate principal amount of $257,500 to Chang Ping Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the "C.L.L."), pursuant to which the Company received $257,500 on September 4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company's common stock, and warrants to purchase 162,908 shares of common stock. As of December 31, 2020, these common shares have been issued. On October 29, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the "Lee Note") in an aggregate principal amount of $250,000 to Hwalin Lee (the "Lee"), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note. On January 19, 2021, the Company paid off the convertible promissory note of $311,233, including principal and accrued and unpaid interest expense. On October 23, 2020, the Company entered into a Securities Purchase Agreement (the "October SPA") with one accredited investor. Pursuant to the October SPA, the Company sold and issued a convertible promissory note (the "October Note") in the principal amount of $2,500,000 to the investor and received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of the October Note is the twenty-four (24) month anniversary from the issuance date (the "Maturity Date"). Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the Company's common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect to convert part or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding amount at any time, in whole or in part, without any penalty. As of December 31, 2020 and 2019, the aggregate carrying values of the convertible debentures were $2,750,000 and $2,007,500, respectively; and accrued convertible interest was $104,551 and $181,852, respectively. Total interest expenses in connection with the above convertible note payable were $240,420 and $145,514 for the year ended December 31, 2020 and 2019, respectively.

Bank Loans

Bank Loans	12 Months Ended
	Dec. 31, 2020
Bank Loans [Abstract]
BANK LOANS	8. BANK LOANS (1) Short-term bank loan consists of the following: December 31, December 31, 2020 2019 Cathay United Bank $ 267,000 $ 250,500 CTBC Bank 712,000 668,000 Cathay Bank 650,000 1,000,000 Total $ 1,629,000 $ 1,918,500 Cathay United Bank On June 28, 2016, BioLite Taiwan and Cathay United Bank entered into a one-year bank loan agreement (the "Cathay United Loan Agreement") in an amount of NT$7,500,000, equivalent to $267,000. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000, equivalent to $267,000. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $267,000 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $267,000 for one year, which is due on September 6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $267,000 for one year, which is due on September 6, 2021. As of December 31, 2020 and 2019, the effective interest rates per annum was 2.1% and 2.22%, respectively. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company's chairman. Interest expenses were $5,280 and $5,395 for the year ended December 31, 2020 and 2019, respectively. CTBC Bank On June 12, 2017 and July 19, 2017, BioLite Taiwan and CTBC Bank entered into short-term saving secured bank loan agreements (the "CTBC Loan Agreements") in an amount of NT$10,000,000, equivalent to $356,000, and NT$10,000,000, equivalent to $356,000, respectively. Both two loans with the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019, BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $712,000 for six months, which is due on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $712,000 for six months, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $712,000 for six months, which is due on January 15, 2021. On January 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $712,000 for six months, which is due on July 15, 2021. The loan balances bear interest at a fixed rate of 1.68% per annum. The loan is secured by the money deposited in a savings account with the CTBC Bank. This loan was also personal guaranteed by the Company's chairman and BioFirst. During the year ended December 31, 2020, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward. Interest expenses were $11,395 and $10,563 for the year ended December 31, 2020 and 2019, respectively. Cathay Bank On January 21, 2019, the Company received a loan in the amount of $500,000 from Cathay Bank (the "Bank") pursuant to a business loan agreement (the "Loan Agreement") entered by and between the Company and Bank on January 8, 2019 and a promissory note (the "Note") executed by the Company on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date (the "Maturity Date") of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the "Regular Interest Rate") equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the "Index") and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate. In connection with the Note and Loan Agreement, on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the "Guaranty") to guaranty the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey, Inc, which became a wholly-owned subsidiary of the Company effective by operation of law on or about February 5, 2019. On December 29, 2020, the Company entered into a new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr. George Lee to be removed as guarantees from the list of Guaranty. In addition, on January 8, 2019, each of the Company and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the "Security Agreement") to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each, a "Grantor", and collectively, the "Grantors") granted security interest in the collaterals as defined therein, comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020. On April 8, 2020 and October 3, 2020, the Company repaid an aggregated principal amount of $350,000. On December 3, 2020, The Company renewed the Loan Agreement with the principal amount of $650,000 for ten months, which is due on October 31, 2021. The outstanding loan balance was $650,000 as of December 31, 2020. Interest expenses were $53,992 and $59,586 for the year ended December 31, 2020 and 2019, respectively. (2) Long-term bank loan consists of the following: December 31, December 31, 2020 2019 Cathay United Bank $ - $ 13,403 Less: current portion of long-term bank loan - (13,403 ) Total $ - $ - Cathay United Bank On April 30, 2010, BioLite Taiwan entered a seven-year bank loan of NT$8,900,000, equivalent to $288,360, with Cathay United Bank. The term started April 30, 2010 with maturity date at April 30, 2017. On April 30, 2017, BioLite Taiwan extended the original loan agreement for additional three years with the new maturity date at April 30, 2020. The loan balance bears interest at a floating rate of prime rate plus variable rates from 0.77% to 1.17%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. The loan was collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company's chairman. On April 30, 2020, the loan was paid off in full. Interest expenses were $63 and $859 for the year ended December 31, 2020 and 2019, respectively.

Paycheck Protection Program Loa

Paycheck Protection Program Loan Payable	12 Months Ended
	Dec. 31, 2020
Paycheck Protection Program Loan Payable [Abstract]
PAYCHECK PROTECTION PROGRAM LOAN PAYABLE	9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE On April 14, 2020, the Company received a loan in the amount of $124,400 under the Paycheck Protection Program ("PPP") administered by the United States Small Business Administration (the "SBA") from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the "Cares Act"), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month's accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments to be due on the same day of each month after that. No collateral or personal guarantees are required. On February 27, 2021, the Company has submitted all required to East West Bank for the application of forgiveness.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2020
Notes Payable [Abstract]
NOTES PAYABLE	10. NOTES PAYABLE In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working capital purpose. As of the date of this report, BioLite Taiwan is still in discussion with the individual with respect to the terms of the unsecured loans. As of December 31, 2020 and 2019, the balance due to this individual amounted to $106,800 and $100,200, respectively. Interest expense was $12,204 and $11,778 for the year ended December 31, 2020 and 2019, respectively.

Short-term Loan

Short-term Loan	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
SHORT-TERM LOAN	11. SHORT-TERM LOAN On February 18, 2020, the Company entered an unsecured loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on August 17, 2020. On August 18, 2020, the Company extended the contract for six months under the same term. Accrued interest expense was $1,302 as of and for the year ended December 31, 2020.

Related Parties Transactions

Related Parties Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	12. RELATED PARTIES TRANSACTIONS The related parties of the company with whom transactions are reported in these financial statements are as follows: Name of entity or Individual Relationship with the Company and its subsidiaries BioFirst Corporation (the "BioFirst") Entity controlled by controlling beneficiary shareholder of YuanGene BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)") 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene Rgene Corporation (the "Rgene") Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene YuanGene Corporation (the "YuanGene") Controlling beneficiary shareholder of the Company AsiaGene Corporation (the "AsiaGene") Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene Eugene Jiang Former President and Chairman Keypoint Technology Ltd. (the "Keypoint') The Chairman of Keypoint is Eugene Jiang's mother. Lion Arts Promotion Inc. (the "Lion Arts") Shareholder of the Company Yoshinobu Odaira (the "Odaira") Director of the Company GenePharm Inc. (the "GenePharm") Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm. Euro-Asia Investment & Finance Corp Ltd. (the "Euro-Asia") Shareholder of the Company LBG USA, Inc. (the "LBG USA") 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene LionGene Corporation (the "LionGene") Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene Kimho Consultants Co., Ltd. (the "Kimho") Shareholder of the Company Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the "Jiangs") Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Amkey Ventures, LLC ("Amkey") An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc BioLite Japan Entity controlled by controlling beneficiary shareholder of ABVC Accounts receivable - related parties Accounts receivable due from related parties consisted of the following as of the periods indicated: December 31, December 31, 2020 2019 GenePharm Inc. $ 142,225 $ 142,225 Rgene - 1,053 Amkey 1,210 - Total $ 143,435 $ 143,278 Due from related parties Amount due from related parties consisted of the following as of the periods indicated: December 31, December 31, 2020 2019 Rgene $ 42,911 $ 36,332 AsiaGene 4,241 3,578 BioFirst - 137,151 BioFirst (Australia) 373,235 40,000 BioHopeKing Corporation 123,583 115,946 LBG USA 675 675 BioLite Japan 150,000 - Keypoint 1,610 - Total $ 696,255 $ 333,682 (1) As of December 31, 2020 and 2019, the Company has advanced an aggregate amount of $31,684 and $29,194 to Rgene for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019. On January 1, 2020, the contract has been renewed for another year, when the new maturity date now is on December 31, 2020. As of December 31, 2020, and December 31, 2019, the outstanding loan balance was $31,684 and $29,194; and accrued interest was $11,227 and $7,138, respectively. (2) On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,560, to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019. On January 1, 2020, the agreement has been renewed for another year, when the new maturity date now is on December 31, 2020. As of December 31, 2020 and 2019, the outstanding loan balance was $3,560 and $3,343, and accrued interest was $681 and $235, respectively. (3) On July 12, 2019, the Company had an aggregate amount of loan with BioFirst of $150,000 to meet its working capital needs, pursuant to which the interest bears at 12% per annum. The Company paid back $21,317 in 2019. The remaining loan balance was $128,683 as of December 31, 2019. This loan is matured on July 11, 2020 and bears interest at 1% per month (or equivalent to 12% per annum). As of December 31, 2020 and 2019, the outstanding loan balance was $0 and $128,683, and accrued interest was $0 and $8,468, respectively. (4) On May 11, 2018, the Company and BioFirst (Australia) entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and are due on demand prior to June 30, 2020. Afterwards, all outstanding load will bear interest rate at 12% per annum. On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $321,487 to properly record R&D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan will be matured on June 30, 2021 with an interest rate of 12% per annum. As of December 31, 2020 and 2019, the outstanding loan balances was $373,235 and $40,000, respectively. (5) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the "BHK") entered into a co-development agreement, (the "BHK Co-Development Agreement", see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2020 and 2019, due from BHK was $123,583 and $115,946, respectively. (6) On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2020 and 2019, the outstanding advance balances were $675. (7) On May 8, 2020, the Company and Lucidaim entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan's working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate. As of December 31, 2020 and 2019, the outstanding advance balances was $150,000 and $0, respectively. (8) On October 31, 2020, the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. As of December 31, 2020, the outstanding loan balance was $1,610. Due to related parties Amount due to related parties consisted of the following as of the periods indicated: December 31, December 31, 2020 2019 LionGene Corporation $ - $ 10,275 BioFirst Corporation 23,647 24,182 AsiaGene - 24,017 YuanGene 9,205 9,205 The Jiangs 16,627 40,031 Kimho - 21,500 Euro Asia - 12,000 Due to shareholders 166,261 284,479 Due to employee 72,704 - Total $ 288,445 $ 425,689 (1) In November 2018, BioLite Taiwan has borrowed an aggregate amount of NT$13,295,000, equivalent to $430,817 from LionGene for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the all of remaining balance of $428,099, to 61,157 shares of the Company's common stock at a conversion price of $7.00 per share. On October 15, 2019, LionGene has advanced funds to the Company for working capital purpose in an aggregate amount of NTD $300,000, equivalent to $10,020, The advances bear 1% interest rate per month. As of December 31, 2020 and 2019, the outstanding principal of loans was $0 and $10,020, and accrued interest was $0 and $255, respectively. Interest expenses in connection with these loans were $955 and $255 for the year ended December 31, 2020 and 2019, respectively. (2) On January 26, 2017, BriVision and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. On February 2, 2019, BriVision and BioFirst agreed to extend the remaining loan balance of $693,000 for one year matured on February 1, 2020. Under the terms of the loan agreement, the loan bears interest at 12% per annum. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $693,000 to 99,000 shares of the Company's common stock at a conversion price of $7.00 per share. Since 2017, BioLite Taiwan and BioFirst entered into several loan agreements for an aggregate amount of NT$19,430,000, equivalent to $625,646, to meet its working capital needs. Under the terms of the loan agreements, the loans bear interest at 12% per annum. The term of the loans has various maturity dates through May 27, 2020. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $625,646 to 89,378 shares of the Company's common stock at a conversion price of $7.00 per share. Since 2017, BioFirst has also advanced funds to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $597,128 to 85,304 shares of the Company's common stock at a conversion price of $7.00 per share. On April 12, 2017, BioLite BVI and BioFirst entered into a loan agreement for NT$30,000,000, equivalent to $987,134 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum). BioLite BVI and BioFirst extended the loan with the same interest rate and amount for one year. The loan will be matured on May 11, 2019. On May 12, 2019, the two parties extended the loan with the same interest rate and amount for one year. The loan will be matured on May 11, 2020. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $987,134 to 141,020 shares of the Company's common stock at a conversion price of $7.00 per share. On July 24, 2017, BriVision entered into a collaborative agreement (the "BioFirst Collaborative Agreement") with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On June 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares of the Company's common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. Since 2019, BioFirst has also advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of December 31, 2020 and 2019, the aggregate amount of outstanding balance and accrued interest is $23,647 and $24,182, respectively. (3) In September 2017, AsiaGene entered an investment and equity transfer agreement (the "Investment and Equity Transfer Agreement") with Everfront Biotech Inc. (the "Everfront"), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $160,000 to 22,858 shares of the Company's common stock at a conversion price of $7.00 per share. As of December 31, 2020 and 2019, AsiaGene has advanced the Company an aggregate amount of $0 and $24,017, respectively for working capital purpose. This advance bears 0% interest rate and is due on demand. (4) On January 18, 2018, the Company and YuanGene entered into a loan agreement for a total of $50,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The maturity date of this loan is January 19, 2019. On January 20, 2019, the two parties extended the loan with the same interest rate and amount for one year. The loan will be matured on January 19, 2020. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $50,000 to 7,143 shares of the Company's common stock at a conversion price of $7.00 per share. In January 2018, YuanGene Corporation has advanced an aggregate amount of $42,690 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $42,690 to 6,099 shares of the Company's common stock at a conversion price of $7.00 per share. As of December 31, 2020 and 2019, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on demand. (5) Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $837,726 to 119,675 shares of the Company's common stock at a conversion price of $7.00 per share. Since 2018, the Jiangs have advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $353,050 to 50,436 shares of the Company's common stock at a conversion price of $7.00 per share. Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2020 and December 31, 2019, the outstanding balance due to the Jiangs amounted to $16,627 and $40,031, respectively. These loans bear interest rate of 0% to 1% per month, and are due on demand. (6) On July 2, 2019, the Company entered into an agreement with Kimho for consulting service, with such services to begin in September 2019. As of December 31, 2020 and 2019, the outstanding services charge was $0 and $21,500, respectively. (7) As of December 31, 2020 and 2019, Euro Asia has advanced of $0 and $12,000, respectively, to the Company for working capital purpose. The advances bear 0% interest rate. (8) Since 2018, the Company's shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate from 12% to 13.6224% per annum. As of December 31, 2020 and 2019, the outstanding principal and accrued interest was $166,261 and $284,479, respectively. Interest expenses in connection with these loans were $21,520 and $14,910 for the year ended December 31, 2020 and 2019, respectively. (9) During the year Ended December 31, 2020, the Company had advances from one employee for working capital purpose. The outstanding balance due to this employee amounted to $72,704 as of December 31, 2020. This loan bears interest rate of 1.5% per annum, and is due on demand.

Equity

Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
EQUITY	13. EQUITY During October 2015, $350,000 of subscription receivable was fully collected from the shareholders. On February 8, 2016, a Share Exchange Agreement ("Share Exchange Agreement") was entered into by and among American BriVision (Holding) Corporation (the "Company"), American BriVision Corporation ("BriVision"), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China ("Euro-Asia"), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the "BriVision Stock"). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the "Acquisition Stock") (subject to adjustment for fractionalized shares as set forth below) of the Company's Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company's Common Stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision's Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company's Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company's Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company's Common Stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the "Share Exchange"), BriVision became a wholly owned subsidiary (the "Subsidiary") of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the "2016 Plan"), 157,050 (50,000 pre-stock split) shares were granted to the employees. On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the "Forward Stock Split") and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. On May 6, 2016, the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company's first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On August 26, 2016, the Company issued 1,468,750 shares ("Shares") of the Company's Common Stock, par value $0.001 (the "Offering") to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the "SPA"). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company's Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company's Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit). On February 8, 2019, after the Merger, the Company issued 74,997,546 shares to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey. On May 3, 2019, the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority ("FINRA"). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company's common stock were exchanged for 17,693,625 shares of the Company's Common Stock. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split. On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama ("Kameyama") for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company's Common Stock at $1.00 per share for any amount exceeding $3,000. The Company's stocks shall be calculated and issued in December every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued 24,694 stock options to Kameyama related to unpaid consulting fees of $49,388 (see Note 14). During the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment & Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party),and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued 644,972 shares of the Company's common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable. As of December 31, 2020 and 2019, stock subscription receivable was $3,160,360 and $4,063,320, respectively. On July 24, 2017, BriVision entered into a collaborative agreement (the "BioFirst Collaborative Agreement") with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On June 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares of the Company's common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. These common shares have been issued during the year ended December 31, 2019. As stated in Note 12, in August 2019, the Company entered into several Conversion Agreements to all creditors that are listed under below table of "due to related parties" in consideration for a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements, creditor agrees to convert the amount of debt into the Company's common stock at a price of $7.00 per share. Amount of Number of Lion Arts Promotion Inc $ 97,864 13,981 LionGene Corporation 428,099 61,157 BioFirst Corporation 2,902,911 414,702 AsiaGene Corporation 160,000 22,858 YuanGene Corporation 92,690 13,242 The Jiangs 1,190,776 170,111 Total $ 4,872,340 696,051 On March 12, 2020, the board of directors of the Company approved and adopted an amendment to the Company's Articles of Incorporation, to increase the authorized shares of its common stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares. On July 8, 2020, the Company entered an agreement with View Trade Securities Inc. ("ViewTrade") to engage ViewTrade as the placement agent and the Company's advisor with respect to its ongoing capital events. Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision. As of December 31, 2020, the Company has issued 60,000 shares of common stock to ViewTrade for the consulting fee with an estimated value of $135,000. The warrants were never issued and the parties mutually agreed to terminate the agreement on November 19, 2020. As a termination fee, the Company agreed to issue ViewTrade 50,000 restricted common shares of the Company. Also on November 19, 2020, the Company and ViewTrade agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only. In addition to a retainer fee, the Company agreed to issue 200,000 warrants, with an exercise price of $2.25, an industry standard cashless exercise provision, and a term of 5 years from November 19, 2020. During the year ended December 31, 2020, the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company agreed to pay the service fee by issuing 50,000 shares of unrestricted common shares, valued at the closing price of $2.9 per share on the grant date. As of December 31, 2020, these shares have been issued. During the year ended December 31, 2020, the Company received aggregated capital contributions of $7,615,331 in cash from 45 investors through private placements of the sale of the Company's common stock for the purchase price of $2.25 per share and a free warrant attached with each common stock purchased. As of December 31, 2020, 3,384,615 shares of the Company's common stock have been issued. During the year ended December 31, 2020, the Company entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee by issuing 521,887 shares of unrestricted common shares, valued at the closing price from $2 to $3.68 per share on the grant date. As of December 31, 2020, these shares have been issued. During the year ended December 31, 2020, the Company issued aggregated common shares of 915,856 to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests, including the debt conversion to the following: a. Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company's common stock, and warrants to purchase 159,145 shares of the Company's common stock. b. Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company's common stock, and warrants to purchase 154,368 shares of the Company's common stock. c. C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company's common stock, and warrants to purchase 162,908 shares of the Company's common stock. d. KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company's common stock, and warrants to purchase 126,530 shares of the Company's common stock. e. Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company's common stock, and warrants to purchase 192,784 shares of the Company's common stock. f. KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company's common stock, and warrants to purchase 120,121 shares of the Company's common stock. See Note 7 for more details in connection with the above debt conversion.

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2020
Paycheck Protection Program Loan Payable [Abstract]
STOCK OPTIONS	14. STOCK OPTIONS On October 30, 2020, the Company issued an aggregate of 545,182 shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive Plan, as amended, at a conversion price of $2 per share; the total amount of converted salaries and consulting fees was $1,090,361. On November 21, 2020, the Company has entered into acknowledgement agreements and stock option purchase agreements with these employees and consultant; pursuant to which the Company granted stock options to purchase 545,182 shares of the Company's common stock in lieu of common stock. The options were vested at the grant date and become exercisable for 10 years from the grant date. Options issued and outstanding as of December 31, 2020, and their activities during the year then ended are as follows: Weighted- Weighted- Average Number of Average Contractual Underlying Exercise Price Life Remaining Aggregate Shares Per Share in Years Intrinsic Value Outstanding as of January 1, 2020 - $ - $   Granted 545,182 2.00 9.89 616,056 Forfeited - - Outstanding as of December 31, 2020 545,182 2.00 9.89 $ 616,056 Exercisable as of December 31, 2020 545,182 2.00 9.89 $ 616,056 Vested and expected to vest 545,182 $ 2.00 9.89 $ 616,056 The fair value of stock options granted for the year ended December 31, 2020 was calculated using the Black-Scholes option-pricing model applying the following assumptions: Year ended December 31, 2019 Risk free interest rate 0.38 % Expected term (in years) 5.00 Dividend yield 0 % Expected volatility 89.01 % The weighted average grant date fair value of options granted during 2020 was $3.13. There are 2,812,949 options available for grant under the 2016 Equity Incentive Plan as of December 31, 2020. Compensation costs associated with the Company's stock options are recognized, based on the grant-date fair values of these options over vesting period. Accordingly, the Company recognized stock-based compensation expense of $1,706,419 and $0 for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, there were no unvested options.

Loss per Share

Loss per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
LOSS PER SHARE	15. LOSS PER SHARE Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the Year Ended December 31, 2020 and 2019. For the Year Ended December 31, December 31, Numerator: Net loss attributable to ABVC's common stockholders $ (9,791,164 ) $ (3,641,776 ) Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding - Basic 19,715,559 17,498,543 Stock options – Weighted-average shares outstanding - Diluted 19,715,559 17,498,543 Loss per share -Basic $ (0.50 ) $ (0.21 ) -Diluted $ (0.50 ) $ (0.21 ) Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.

Lease

Lease	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
LEASE	16. LEASE The Company adopted FASB Accounting Standards Codification, Topic 842, Leases ("ASC 842") using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019. As such, the disclosures required under ASC 842 are not presented for periods before the date of adoption. For the comparative periods prior to adoption, the Company presented the disclosures which were required under ASC 840. The Company applied the following practical expedients in the transition to the new standard and allowed under ASC 842: ● Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases. ● Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets. ● Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02. ● Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately. ● Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months. The new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use ("ROU") assets and lease liabilities. ROU assets represent the Company's right to use underlying assets for the lease terms and lease liabilities represent the Company's obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company's future minimum based payments used to determine the Company's lease liabilities mainly include minimum based rent payments. As most of Company's leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months as of January 1, 2019. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized lease incentives provided by lessors, and restructuring liabilities. The adoption of ASC 842 had a substantial impact on the Company's consolidated balance sheets. The most significant impact was the recognition of the operating lease right-of-use assets and the liability for operating leases. Accordingly, adoption of this standard resulted in the recognition of operating lease right-of-use assets of $577,830 and operating lease liabilities of $598,937 comprised of $301,105 of current operating lease liabilities and $297,832 of non-current operating lease liabilities on the consolidated balance sheet as of January 1, 2019. The adoption of ASC 842 also resulted in a cumulative-effect adjustment of $(21,107) to the opening balance of accumulated deficit. In addition, the adoption of the standard did not have a material impact on the Company's results of operations or cash flows. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has no finance leases. The Company's leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements. The Company's operating leases have remaining lease terms of up to approximately five years. December 31, December 31, ASSETS Operating lease right-of-use assets $ 1,772,747 $ 524,445 LIABILITIES Operating lease liabilities (current) 316,178 304,248 Operating lease liabilities (noncurrent) 1,456,567 235,555 Supplemental Information The following provides details of the Company's lease expenses: Year Ended 2020 2019 Operating lease expenses $ 337,282 $ 301,437 Other information related to leases is presented below: Year Ended 2020 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 337,282 $ 301,437 December 31, December 31, Weighted Average Remaining Lease Term: Operating leases 3.08 years 3.08 years Weighted Average Discount Rate: Operating leases 0.55 % 0.55 % The minimum future annual payments under non-cancellable leases during the next five years and thereafter, at rates now in force, are as follows: Operating leases 2021 $ 324,788 2022 341,527 2023 358,431 2024 375,337 2025 338,676 Thereafter 56,916 Total future minimum lease payments, undiscounted 1,795,675 Less: Imputed interest 22,930 Present value of future minimum lease payments $ 1,772,745

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
BUSINESS COMBINATION	17. BUSINESS COMBINATION On February 8, 2019, the Company consummated the Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, "Business Combination" to record the merger transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey's results of operations were included in the Company's results beginning February 8, 2019. The purchase price has been allocated to the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following: Purchase consideration: Common Stock (*) $ 44,341,847 Allocation of the purchase price: Cash and cash equivalents $ 531,147 Accounts receivable, net 188,550 Property and equipment, net 56,075 Operating lease right-of-use assets 485,684 Security deposits 10,440 Total assets acquired 1,271,896 Accounts payable (56,204 ) Accrued expenses and other current liabilities (251,335 ) Operating lease liability (267,256 ) Tenant security deposit (2,880 ) Total liabilities assumed (577,675 ) Total net assets acquired 694,221 Goodwill as a result of the Merger $ 43,647,626 * 29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019. On February 8, 2019, the Company has recorded a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of the Company and the Company's inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company's anticipated future cash flows indicate that the recoverability of goodwill is not reasonably assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation of the Merger.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	18. SUBSEQUENT EVENTS On February 7, 2021, the entity of ABVC received a loan in the amount of $104,167 under the Paycheck Protection Program ("PPP") administered by the United States Small Business Administration (the "SBA") from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the "Cares Act"), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month's accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments to be due on the same day of each month after that. No collateral or personal guarantees are required. On January 29, 2021, the entity of BioKey received a loan in the amount of $132,331 under the Paycheck Protection Program ("PPP") administered by the United States Small Business Administration (the "SBA") from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the "Cares Act"), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month's accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments to be due on the same day of each month after that. No collateral or personal guarantees are required. The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of December 31, 2020 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, "Subsequent Events."

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the "U.S. GAAP"). All significant intercompany transactions and account balances have been eliminated. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company's financial statements are expressed in U.S. dollars.
Fiscal Year	Fiscal Year The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.
Inventory	Inventory Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.
Reclassifications	Reclassifications Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.
Forward Stock split	Forward Stock Split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.
Stock Reverse Split	Stock Reverse Split On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized common stock of the Company (the "Common Stock") and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.
Fair Value Measurements	Fair Value Measurements FASB ASC 820, "Fair Value Measurements" defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows: ● Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available. ● Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability. The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company's short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company's long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2020 and December 31, 2019, the Company's cash and cash equivalents amounted 4,273,208 and $144,295, respectively. Some of the Company's cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.
Restricted Cash Equivalents	Restricted Cash Equivalents Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of December 31, 2020 and December 31, 2019, the Company's restricted cash equivalents amounted $728,163 and $16,148, respectively.
Concentration of Credit Risk	Concentration of Credit Risk The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation's insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.
Revenue Recognition	Revenue Recognition During the fiscal year 2018, the Company adopted Accounting Standards Codification ("ASC"), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company's reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company's review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company's revenue during all periods presented. Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The following are examples of when the Company recognizes revenue based on the types of payments the Company receives. Collaborative Revenues — As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&D personnel costs, discount rates and probabilities of technical and regulatory success. The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company's deliverables requires the use of management's judgment. Significant factors considered in management's evaluation of the estimated performance periods include, but are not limited to, the Company's experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition. (i) Non-refundable upfront payments If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements. (ii) Milestone payments The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company's obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company's obligations under the collaborative agreement with collaboration partners. The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs. (iii) Multiple Element Arrangements The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s). The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company's contractual or estimated performance period for the undelivered elements, which is typically the term of the Company's research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date. At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company's performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met. (iv) Royalties and Profit Sharing Payments Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved. Revenues Derived from Research and Development Activities Services — Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation. If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations. The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company's transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price. The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.
Property and Equipment	Property and Equipment Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives: Estimated Life Buildings and leasehold improvements 5 ~ 50 Machinery and equipment 5 ~ 10 Office equipment 3 ~ 6
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment ("ASC 360-10"). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.
Long-term Equity Investment	Long-term Equity Investment The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as: ● Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments. ● Non-marketable cost method investments when the equity method does not apply. Significant judgment is required to identify whether an impairment exists in the valuation of the Company's non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee's industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees' revenue, costs, and discount rates. The Company's assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.
Other-Than-Temporary Impairment	Other-Than-Temporary Impairment The Company's long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows: ● Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee's credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments. ● Non-marketable equity investments based on the Company's assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee's ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $961,217 and $0 for the year ended December 31, 2020 and 2019, respectively.
Goodwill	Goodwill The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions. The Company completed the required testing of goodwill for impairment as of December 31, 2020, and determined that goodwill was impaired because of the current financial condition of the Company and the Company's inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.
Research and Development Expenses	Research and Development Expenses The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred. For CDMO business unit, the Company accounts for R&D costs in accordance with Accounting Standards Codification ("ASC") 730, Research and Development ("ASC 730"). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.
Post-retirement and post-employment benefits	Post-retirement and post-employment benefits The Company's subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the "Act") in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker's monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees' salaries to the employees' pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $13,961and $15,928 for the year ended December 31, 2020 and 2019, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.
Stock-based Compensation	Stock-based Compensation The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation". Total employee stock-based compensation expenses were $1,623,102 and $0 for the year ended December 31, 2020 and 2019, respectively. The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation" and FASB ASC Topic 505-50 "Equity-Based Payments to Non-Employees" which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $2,523,877 and $22,314 for the year ended December 31, 2020 and 2019, respectively.
Beneficial Conversion Feature	Beneficial Conversion Feature From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the year ended December 31, 2020 and 2019. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. On December 22, 2017, the SEC issued Staff Accounting Bulletin ("SAB 118"), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company's accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.
Valuation of Deferred Tax Assets	Valuation of Deferred Tax Assets A valuation allowance is recorded to reduce the Company's deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company's projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.
Loss Per Share of Common Stock	Loss Per Share of Common Stock The Company calculates net loss per share in accordance with ASC Topic 260, "Earnings per Share". Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.
Commitments and Contingencies	Commitments and Contingencies The Company has adopted ASC Topic 450 "Contingencies" subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.
Foreign-currency Transactions	Foreign-currency Transactions For the Company's subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars ("NTD") at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders' Equity (Deficit).
Translation Adjustment	Translation Adjustment The accounts of the Company's subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar ("NT$"). Such financial statements were translated into U.S. Dollars ("$" or "USD") in accordance ASC 830, "Foreign Currency Matters", with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder's deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders' equity (deficit).
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Income Taxes In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity's Own Equity (Subtopic 815-40)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of property and equipment	Estimated Life Buildings and leasehold improvements 5 ~ 50 Machinery and equipment 5 ~ 10 Office equipment 3 ~ 6

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Schedule of inventory	December 31, December 31, Finished goods $ 100,967 $ 94,727 Work-in-process 22,038 20,676 Raw materials 61,718 57,904 Allowance for inventory valuation and obsolescence loss (184,723 ) (173,307 ) Inventory, net $ - $ -

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	December 31, December 31, Land $ 395,645 $ 371,195 Buildings and leasehold improvements 2,233,573 2,225,386 Machinery and equipment 994,544 987,234 Office equipment 189,760 178,409 3,813,522 3,762,224 Less: accumulated depreciation (3,298,688 ) (3,241,294 ) Property and equipment, net $ 514,834 $ 520,930

Long-Term Investments (Tables)

Long-Term Investments (Tables)	12 Months Ended
	Dec. 31, 2020
Schedule of ownership percentages of investee	Ownership percentage December 31, December 31, Accounting Name of related party 2020 2019 treatments Braingenesis Biotechnology Co., Ltd. 0.17 % 0.17 % Cost Method Genepharm Biotech Corporation 0.70 % 0.72 % Cost Method BioHopeKing Corporation 5.90 % 7.13 % Cost Method BioFirst Corporation 15.99 % 15.89 % Equity Method Rgene Corporation 31.62 % 31.61 % Equity Method
Schedule of extent the investee relies	Name of related party The extent the investee relies on the Company for its business Braingenesis Biotechnology Co., Ltd. No specific business relationship Genepharm Biotech Corporation No specific business relationship BioHopeKing Corporation Collaborating with the Company to develop and commercialize drugs BioFirst Corporation Loaned from the investee and provides research and development support service Rgene Corporation Collaborating with the Company to develop and commercialize drugs
Schedule of long-term investment	December 31, December 31, Non-marketable Cost Method Investments, net Braingenesis Biotechnology Co., Ltd. $ 7,853 $ 7,367 Genepharm Biotech Corporation 23,974 22,493 BioHopeKing Corporation 890,564 1,998,310 Sub total 922,391 2,028,170 Equity Method Investments, net BioFirst Corporation 268,336 1,336,449 Rgene Corporation - - Total $ 1,190,727 $ 3,364,619
Schedule of equity investments	Year Ended 2020 2019 Share of equity method investee losses $ (1,168,733 ) $ (210,086 )
BioFirst [Member]
Schedule of balance sheets	December 31, December 31, Current Assets $ 1,299,822 $ 1,350,701 Noncurrent Assets 2,540,041 7,450,032 Current Liabilities 1,986,340 2,060,460 Noncurrent Liabilities 73,197 78,888 Stockholders' Equity 1,780,326 6,661,385
Schedule of statements of operation	Year Ended 2020 2019 Net sales $ 257,235 $ 43,975 Gross profit 10,121 (37,160 ) Net loss (5,401,074 ) (972,303 ) Share of losses from investments accounted for using the equity method (1,168,733 ) (210,086 )
Rgene [Member]
Schedule of balance sheets	December 31, December 31, Current Assets $ 123,958 $ 82,254 Noncurrent Assets 412,342 62,768 Current Liabilities 1,392,756 312,950 Noncurrent Liabilities 38,953 - Shareholders' Deficit (895,409 ) (167,928 )
Schedule of statements of operation	Year Ended 2020 2019 Net sales $ 16,595 $ - Gross Profit (335,735 ) - Net loss (641,636 ) (53,877 ) Share of loss from investments accounted for using the equity method - -

Bank Loans (Tables)

Bank Loans (Tables)	12 Months Ended
	Dec. 31, 2020
Bank Loans [Abstract]
Schedule of short-term bank loan	December 31, December 31, 2020 2019 Cathay United Bank $ 267,000 $ 250,500 CTBC Bank 712,000 668,000 Cathay Bank 650,000 1,000,000 Total $ 1,629,000 $ 1,918,500
Schedule of long-term bank loan	December 31, December 31, 2020 2019 Cathay United Bank $ - $ 13,403 Less: current portion of long-term bank loan - (13,403 ) Total $ - $ -

Related Parties Transactions (T

Related Parties Transactions (Tables)	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Schedule of related party transactions	Name of entity or Individual Relationship with the Company and its subsidiaries BioFirst Corporation (the "BioFirst") Entity controlled by controlling beneficiary shareholder of YuanGene BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)") 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene Rgene Corporation (the "Rgene") Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene YuanGene Corporation (the "YuanGene") Controlling beneficiary shareholder of the Company AsiaGene Corporation (the "AsiaGene") Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene Eugene Jiang Former President and Chairman Keypoint Technology Ltd. (the "Keypoint') The Chairman of Keypoint is Eugene Jiang's mother. Lion Arts Promotion Inc. (the "Lion Arts") Shareholder of the Company Yoshinobu Odaira (the "Odaira") Director of the Company GenePharm Inc. (the "GenePharm") Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm. Euro-Asia Investment & Finance Corp Ltd. (the "Euro-Asia") Shareholder of the Company LBG USA, Inc. (the "LBG USA") 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene LionGene Corporation (the "LionGene") Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene Kimho Consultants Co., Ltd. (the "Kimho") Shareholder of the Company Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the "Jiangs") Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Amkey Ventures, LLC ("Amkey") An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc BioLite Japan Entity controlled by controlling beneficiary shareholder of ABVC
Schedule of accounts receivable due from related parties	December 31, December 31, 2020 2019 GenePharm Inc. $ 142,225 $ 142,225 Rgene - 1,053 Amkey 1,210 - Total $ 143,435 $ 143,278
Schedule of amount due from related parties	December 31, December 31, 2020 2019 Rgene $ 42,911 $ 36,332 AsiaGene 4,241 3,578 BioFirst - 137,151 BioFirst (Australia) 373,235 40,000 BioHopeKing Corporation 123,583 115,946 LBG USA 675 675 BioLite Japan 150,000 - Keypoint 1,610 - Total $ 696,255 $ 333,682
Schedule of amount due to related parties	December 31, December 31, 2020 2019 LionGene Corporation $ - $ 10,275 BioFirst Corporation 23,647 24,182 AsiaGene - 24,017 YuanGene 9,205 9,205 The Jiangs 16,627 40,031 Kimho - 21,500 Euro Asia - 12,000 Due to shareholders 166,261 284,479 Due to employee 72,704 - Total $ 288,445 $ 425,689

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Schedule of converted amount of debt and shares	Amount of Number of Lion Arts Promotion Inc $ 97,864 13,981 LionGene Corporation 428,099 61,157 BioFirst Corporation 2,902,911 414,702 AsiaGene Corporation 160,000 22,858 YuanGene Corporation 92,690 13,242 The Jiangs 1,190,776 170,111 Total $ 4,872,340 696,051

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2020
Paycheck Protection Program Loan Payable [Abstract]
Schedule of options issued and outstanding	Weighted- Weighted- Average Number of Average Contractual Underlying Exercise Price Life Remaining Aggregate Shares Per Share in Years Intrinsic Value Outstanding as of January 1, 2020 - $ - $   Granted 545,182 2.00 9.89 616,056 Forfeited - - Outstanding as of December 31, 2020 545,182 2.00 9.89 $ 616,056 Exercisable as of December 31, 2020 545,182 2.00 9.89 $ 616,056 Vested and expected to vest 545,182 $ 2.00 9.89 $ 616,056
Schedule of fair value of stock options granted	Year ended December 31, 2019 Risk free interest rate 0.38 % Expected term (in years) 5.00 Dividend yield 0 % Expected volatility 89.01 %

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of loss per share	For the Year Ended December 31, December 31, Numerator: Net loss attributable to ABVC's common stockholders $ (9,791,164 ) $ (3,641,776 ) Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding - Basic 19,715,559 17,498,543 Stock options – Weighted-average shares outstanding - Diluted 19,715,559 17,498,543 Loss per share -Basic $ (0.50 ) $ (0.21 ) -Diluted $ (0.50 ) $ (0.21 )

Lease (Tables)

Lease (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of operating lease arrangements	December 31, December 31, ASSETS Operating lease right-of-use assets $ 1,772,747 $ 524,445 LIABILITIES Operating lease liabilities (current) 316,178 304,248 Operating lease liabilities (noncurrent) 1,456,567 235,555
Schedule of supplemental information related to operating leases	Year Ended 2020 2019 Operating lease expenses $ 337,282 $ 301,437 Year Ended 2020 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 337,282 $ 301,437 December 31, December 31, Weighted Average Remaining Lease Term: Operating leases 3.08 years 3.08 years Weighted Average Discount Rate: Operating leases 0.55 % 0.55 %
Schedule of minimum future annual payments under non-cancellable leases	Operating leases 2021 $ 324,788 2022 341,527 2023 358,431 2024 375,337 2025 338,676 Thereafter 56,916 Total future minimum lease payments, undiscounted 1,795,675 Less: Imputed interest 22,930 Present value of future minimum lease payments $ 1,772,745

Business Combination (Tables)

Business Combination (Tables)	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Schedule of assets acquired and liabilities assumed based on fair value	Purchase consideration: Common Stock (*) $ 44,341,847 Allocation of the purchase price: Cash and cash equivalents $ 531,147 Accounts receivable, net 188,550 Property and equipment, net 56,075 Operating lease right-of-use assets 485,684 Security deposits 10,440 Total assets acquired 1,271,896 Accounts payable (56,204 ) Accrued expenses and other current liabilities (251,335 ) Operating lease liability (267,256 ) Tenant security deposit (2,880 ) Total liabilities assumed (577,675 ) Total net assets acquired 694,221 Goodwill as a result of the Merger $ 43,647,626 * 29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.

Organization and Description _2

Organization and Description of Business (Details) - shares	Feb. 08, 2019	Feb. 08, 2016	Aug. 31, 2017
Organization and Description of Business (Textual)
Percentage of common shares issued and outstanding			73.00%
Share Exchange Agreement [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split		164,387,376
Common stock issued pre-stock split		52,336,000
Share Exchange Agreement One [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split		166,273,921
Common stock issued pre-stock split		52,936,583
Share Exchange Agreement Two [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split		163,159,952
Common stock issued pre-stock split		51,945,225
Percentage of common shares issued and outstanding		79.70%
Percentage of issued share capital		100.00%
Share Exchange Agreement Three [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split		166,273,921
Common stock issued pre-stock split		52,936,583
Common stock converted to exchange ratio		0.2536-for-1
Share Exchange Agreement Four [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split		205,519,223
Common stock issued pre-stock split		65,431,144
Merger Agreement [Member]
Organization and Description of Business (Textual)
Common stock issued pre-stock split	104,558,777

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2020
Buildings and leasehold improvements [Member] | Minimum [Member]
Estimated Life	5 years
Buildings and leasehold improvements [Member] | Maximum [Member]
Estimated Life	50 years
Machinery and equipment [Member] | Minimum [Member]
Estimated Life	5 years
Machinery and equipment [Member] | Maximum [Member]
Estimated Life	10 years
Office equipment [Member] | Minimum [Member]
Estimated Life	3 years
Office equipment [Member] | Maximum [Member]
Estimated Life	6 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Textual) - USD ($)	May 03, 2019	Mar. 12, 2019	Mar. 21, 2016	Dec. 31, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies (Textual)
Reverse split ratio	The Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.	i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized common stock of the Company (the "Common Stock") and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes.	1 to 3.141
Common stock, par value			$ 0.001	$ 0.001	$ 0.001
Common stock, authorized			360,000,000	100,000,000	100,000,000
Cash and cash equivalents				$ 4,273,208	$ 144,295
Restricted cash equivalents				728,163	16,148
Impairments of equity investments				961,217	0
Employee stock-based compensation expenses				1,623,102	0
Non-employee stock-based compensation expenses				2,523,877	22,314
Employee benefits amount				$ 13,961	$ 15,928
Percentage of monthly contribution				6.00%

Collaborative Agreements (Detai

Collaborative Agreements (Details) - USD ($)

1 Months Ended

12 Months Ended

Dec. 24, 2018

Sep. 30, 2017

Sep. 25, 2017

May 26, 2017

Aug. 31, 2016

Jul. 27, 2016

Dec. 31, 2015

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Oct. 30, 2020

Aug. 05, 2019

Jun. 30, 2019

Collaborative Agreements (Textual)

Share price

$ 2

Outstanding balance

$ 696,255

$ 333,682

Milestone payments royalty percentage

12.00%

12.00%

BHK Co-Development Agreement [Member]

Collaborative Agreements (Textual)

Description of payment settlement

● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment.

Upfront payments

$ 1,000,000

$ 1,000,000

Percentage of payments under co-development agreement

10.00%

10.00%

Milestone payments to BioLite in cash

$ 31,649,000

$ 10,000,000

Common stock newly issued, value

$ 1,000,000

$ 10,000,000

Collaborative agreements, description

The Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK.

In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of December 31, 2020 and 2019, the Company has not earned the royalty under the BHK Collaborative Agreements.

Co-Dev Agreement [Member]

Collaborative Agreements (Textual)

Amount received from BriVision

$ 3,000,000

$ 3,000,000

$ 450,000

Percentage of payments under co-development agreement

50.00%

Company cash payments

$ 3,000,000

$ 3,000,000

Co-Dev agreement, description

The Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.

BioFirst Stock Purchase Agreement [Member]

Collaborative Agreements (Textual)

Amount received from BriVision

$ 2,902,911

$ 3,000,000

Shares issued

414,702

428,571

Collaborative Arrangement [Member]

Collaborative Agreements (Textual)

Percentage of payments under co-development agreement

50.00%

Common stock newly issued, value

$ 3,000,000

Licensing rights

$ 3,000,000

Company cash payments

$ 3,000,000

Research and development expense

$ 3,000,000

Inventory (Details)

Inventory (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished goods	$ 100,967	$ 94,727
Work-in-process	22,038	20,676
Raw materials	61,718	57,904
Allowance for inventory valuation and obsolescence loss	(184,723)	(173,307)
Inventory, net

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Subtotal	$ 3,813,522	$ 3,762,224
Less: accumulated depreciation	(3,298,688)	(3,241,294)
Property and equipment, net	514,834	520,930
Land [Member]
Subtotal	395,645	371,195
Buildings and leasehold improvements [Member]
Subtotal	2,233,573	2,225,386
Machinery and equipment [Member]
Subtotal	994,544	987,234
Office equipment [Member]
Subtotal	$ 189,760	$ 178,409

Property and Equipment (Detai_2

Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property and Equipment (Textual)
Depreciation expenses	$ 37,142	$ 55,086

Long-Term Investments (Details)

Long-Term Investments (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Braingenesis Biotechnology Co., Ltd [Member]
Ownership percentage	0.17%	0.17%
Accounting treatments	Cost Method
Genepharm Biotech Corporation [Member]
Ownership percentage	0.70%	0.72%
Accounting treatments	Cost Method
BioHopeKing Corporation [Member]
Ownership percentage	5.90%	7.13%
Accounting treatments	Cost Method
BioFirst Corporation [Member]
Ownership percentage	15.99%	15.89%
Accounting treatments	Equity Method
Rgene Corporation [Member]
Ownership percentage	31.62%	31.61%
Accounting treatments	Equity Method

Long-Term Investments (Details

Long-Term Investments (Details 1)	12 Months Ended
	Dec. 31, 2020
BioFirst Corporation [Member]
Relationship with the Company and its subsidiaries, description	Entity controlled by controlling beneficiary shareholder of Yuangene
Braingenesis Biotechnology Co., Ltd. [Member]
Relationship with the Company and its subsidiaries, description	No specific business relationship
Genepharm Biotech Corporation [Member]
Relationship with the Company and its subsidiaries, description	No specific business relationship
BioHopeKing Corporation [Member]
Relationship with the Company and its subsidiaries, description	Collaborating with the Company to develop and commercialize drugs
Rgene Corporation [Member]
Relationship with the Company and its subsidiaries, description	Collaborating with the Company to develop and commercialize drugs

Long-Term Investments (Detail_2

Long-Term Investments (Details 2) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Non-marketable Cost Method Investments, net
Sub total	$ 922,391	$ 2,028,170
Total	1,190,727	3,364,619
BioFirst Corporation [Member]
Non-marketable Cost Method Investments, net
Total	268,336	1,336,449
Rgene Corporation [Member]
Non-marketable Cost Method Investments, net
Total
Braingenesis Biotechnology Co., Ltd. [Member]
Non-marketable Cost Method Investments, net
Sub total	7,853	7,367
Genepharm Biotech Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	23,974	22,493
BioHopeKing Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	$ 890,564	$ 1,998,310

Long-Term Investments (Detail_3

Long-Term Investments (Details 3) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets	$ 6,172,966	$ 878,238
Current Liabilities	4,844,391	6,814,193
Stockholders' Equity	3,438,340	(150,964)
BioFirst [Member]
Current Assets	1,299,822	1,350,701
Noncurrent Assets	2,540,041	7,450,032
Current Liabilities	1,986,340	2,060,460
Noncurrent Liabilities	73,197	78,888
Stockholders' Equity	1,780,326	6,661,385
Rgene [Member]
Current Assets	123,958	82,254
Noncurrent Assets	412,342	62,768
Current Liabilities	1,392,756	312,950
Noncurrent Liabilities	38,953
Stockholders' Equity	$ (895,409)	$ (167,928)

Long-Term Investments (Detail_4

Long-Term Investments (Details 4) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net sales	$ 483,045	$ 701,719
Gross profit	464,329	681,582
Share of losses from investments accounted for using the equity method	(40,589)
BioFirst [Member]
Net sales	257,235	43,975
Gross profit	10,121	(37,160)
Net loss	(5,401,074)	(972,303)
Share of losses from investments accounted for using the equity method	(1,168,733)	(210,086)
Rgene [Member]
Net sales	16,595
Gross profit	(335,735)
Net loss	(641,636)	(53,877)
Share of losses from investments accounted for using the equity method

Long-Term Investments (Detail_5

Long-Term Investments (Details 5) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Long-Term Investment [Abstract]
Share of equity method investee losses	$ (1,168,733)	$ (210,086)

Long-Term Investments (Detail_6

Long-Term Investments (Details Textual)	Nov. 09, 2020	Dec. 31, 2020	Dec. 31, 2019
Long-Term Investments (Textual)
Sale of common stock, description	The Company entered into an agreement with "KSL". The aggregate principal amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company's common stock and warrants for a purchase price of $270,272. As of December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company's common stock.
Rgene [Member]
Long-Term Investments (Textual)
Percentage of common stock shares		31.62%	31.61%
BioFirst [Member]
Long-Term Investments (Textual)
Percentage of common stock shares		15.99%	15.89%
Sale of common stock, description		The Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the same period.

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)

Jan. 19, 2021

Nov. 09, 2020

Oct. 29, 2019

Oct. 23, 2019

Sep. 04, 2019

Jul. 10, 2019

Jun. 27, 2018

May 09, 2018

Aug. 28, 2019

May 30, 2019

Aug. 25, 2018

Dec. 31, 2020

Dec. 31, 2019

Apr. 14, 2020

Convertible Notes Payable (Textual)

Principal amount

$ 124,400

Equity offering, description

The Company entered into an agreement with "KSL". The aggregate principal amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company's common stock and warrants for a purchase price of $270,272. As of December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company's common stock.

Subsequent Event [Member]

Convertible Notes Payable (Textual)

Convertible promissory note received

$ 311,233

Convertible Promissory Note [Member]

Convertible Notes Payable (Textual)

Accrued convertible interest

$ 306,667

Unsecured convertible promissory note [Member]

Convertible Notes Payable (Textual)

Principal amount

$ 250,000

$ 257,500

$ 250,000

$ 250,000

$ 300,000

$ 200,000

$ 250,000

$ 250,000

Bears interest rate

20.00%

20.00%

20.00%

8.00%

8.00%

20.00%

20.00%

8.00%

Convertible promissory note received

$ 250,000

$ 257,500

$ 90,000

$ 250,000

$ 300,000

$ 200,000

$ 160,000

$ 250,000

Equity offering, description

The Company received $250,000 on October 29, 2019. The Lee Note bears interest at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020.

The Company received $160,000 and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020. At any time from the issuance date until the KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price

The Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an “Equity Offering”) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note.

The Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an “Equity Offering”) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note.

The Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum. The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020.

The Company received $160,000 and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020. At any time from the issuance date until the KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price

In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price

Conversion price, description

(i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note. On January 19, 2021, the Company paid off the convertible promissory note of $311,233, including principal and accrued and unpaid interest expense.

(i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company's common stock, and warrants to purchase 162,908 shares of common stock. As of December 31, 2020, these common shares have been issued.

(i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note. As of December 31, 2020, the Company paid off the convertible promissory note of $306,667, including principal and accrued and unpaid interest expense.

(i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Keypoint" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Keypoint". The aggregate principal amount plus accrued interest expenses were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company's common stock, and warrants to purchase 159,145 shares of the Company's common stock. As of December 31, 2020, these common shares have been issued.

(i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Yu and Wei" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Yu and Wei". The aggregate principal amount plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company's common stock, and warrants to purchase 192,784 shares of the Company's common stock. As of December 31, 2020, these common shares have been issued.

(i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company's common stock, and warrants to purchase 126,530 shares of common stock. As of December 31, 2020, these common shares have been issued.

(i) $0.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company entered into an agreement with "KSL". The aggregate principal amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company's common stock and warrants for a purchase price of $270,272. As of December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company's common stock.

(i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21, 2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Odaira" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Odaira". The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company's common stock, and warrants to purchase 154,368 shares of the Company's common stock. As of December 31, 2020, these common shares have been issued.

Convertible debenture

2,750,000

$ 2,007,500

Accrued convertible interest

104,551

181,852

Total interest expenses

$ 240,420

$ 145,514

Securities Purchase Agreement [Member]

Convertible Notes Payable (Textual)

Conversion price, description

Pursuant to the October SPA, the Company sold and issued a convertible promissory note (the “October Note”) in the principal amount of $2,500,000 to the investor and received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of the Note is the twenty-four (24) month anniversary from the issuance date (the “Maturity Date”). Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the Company’s common stock at a fixed conversion price of $2.25 per share.

Bank Loans (Details)

Bank Loans (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total	$ 1,629,000	$ 1,918,500
Cathay United Bank [Member]
Total	267,000	250,500
CTBC Bank [Member]
Total	712,000	668,000
Cathay Bank [Member]
Total	$ 650,000	$ 1,000,000

Bank Loans (Details 1)

Bank Loans (Details 1) - Cathay United Loan Agreement [Member] - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Cathay United Bank		$ 13,403
Less: current portion of long-term bank loan		(13,403)
Total

Bank Loans (Details Textual)

Bank Loans (Details Textual) - USD ($)

Jul. 17, 2020

Apr. 14, 2020

Sep. 06, 2019

Jan. 08, 2019

Oct. 02, 2018

Sep. 06, 2017

Jun. 12, 2017

Mar. 31, 2020

Jan. 19, 2020

Jul. 18, 2019

Feb. 18, 2019

Jan. 21, 2019

Jan. 17, 2019

Jul. 19, 2017

Apr. 30, 2017

Jun. 28, 2016

Apr. 30, 2010

Dec. 31, 2020

Dec. 31, 2019

Jan. 15, 2021

Dec. 03, 2020

Oct. 03, 2020

Apr. 30, 2020

Apr. 08, 2020

Sep. 30, 2019

Sep. 06, 2016

Bank Loans (Textual)

Principal amount

$ 124,400

Maturity date

Apr. 13, 2022

Bears interest rate

1.00%

Cathay United Loan Agreement [Member]

Bank Loans (Textual)

Principal amount

$ 267,000

$ 267,000

$ 267,000

$ 267,000

$ 267,000

Maturity date

Jun. 28, 2017

Debt instrument term

1 year

1 year

1 year

1 year

Bears interest rate

1.15%

Debt instrument due date

Sep. 6, 2020

Sep. 6, 2019

Sep. 6, 2018

Interest expenses

$ 5,280

$ 5,395

Cathay United Loan Agreement [Member] | NT [Member]

Bank Loans (Textual)

Principal amount

$ 7,500,000

$ 7,500,000

$ 7,500,000

$ 7,500,000

$ 7,500,000

CTBC Loan Agreements [Member]

Bank Loans (Textual)

Principal amount

$ 712,000

$ 356,000

$ 712,000

$ 712,000

$ 356,000

Maturity date

Jan. 15, 2021

Jan. 19, 2018

Jul. 19, 2020

Jan. 17, 2020

Jul. 18, 2019

Jan. 19, 2018

Debt instrument term

6 months

1 year

6 months

6 months

1 year

1 year

Bears interest rate

1.68%

Interest expenses

11,395

10,563

CTBC Loan Agreements [Member] | Subsequent Event [Member]

Bank Loans (Textual)

Principal amount

$ 712,000

CTBC Loan Agreements [Member] | NT [Member]

Bank Loans (Textual)

Principal amount

$ 20,000,000

$ 10,000,000

$ 20,000,000

$ 20,000,000

$ 10,000,000

CTBC Loan Agreements [Member] | NT [Member] | Subsequent Event [Member]

Bank Loans (Textual)

Principal amount

$ 20,000,000

Loan Agreement [Member]

Bank Loans (Textual)

Principal amount

$ 1,000,000

$ 650,000

$ 350,000

$ 350,000

Maturity date

Jan. 1, 2020

Received loan amount

$ 500,000

Exceeding amount

$ 500,000

Regular interest rate, description

The Company extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020.

The Note executed in connection with the Loan Agreement bears an interest rate (the "Regular Interest Rate") equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the "Index") and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate.

Cathay United Bank [Member]

Bank Loans (Textual)

Maturity date

Apr. 30, 2020

Bears interest rate

2.10%

2.22%

Cathay United Bank [Member] | April 30, 2010 [Member]

Bank Loans (Textual)

Principal amount

$ 8,900,000

Maturity date

Apr. 30, 2017

Debt instrument term

7 years

Cathay United Bank [Member] | Minimum [Member]

Bank Loans (Textual)

Bears interest rate

0.77%

Cathay United Bank [Member] | Maximum [Member]

Bank Loans (Textual)

Bears interest rate

1.17%

Cathay United Bank [Member] | NT [Member] | April 30, 2010 [Member]

Bank Loans (Textual)

Principal amount

$ 8,900,000

Cathay Bank [Member]

Bank Loans (Textual)

Interest expenses

$ 53,992

$ 59,586

Received loan amount

$ 250,000

Outstanding loan balance

$ 750,000

Paycheck Protection Program L_2

Paycheck Protection Program Loan Payable (Details)	Apr. 14, 2020USD ($)
Paycheck Protection Program Loan Payable (Textual)
Principal amount	$ 124,400
Maturity date	Apr. 13, 2022
Bears interest rate	1.00%
PAYCHECK PROTECTION PROGRAM [Member]
Paycheck Protection Program Loan Payable (Textual)
Paycheck protection program, description	The Company received a loan in the amount of $124,400 under the Paycheck Protection Program ("PPP") administered by the United States Small Business Administration (the "SBA") from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the "Cares Act"), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll.

Notes Payable (Details)

Notes Payable (Details) - BioLite Taiwan [Member] - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Notes Payable (Textual)
Interest expenses		$ 12,204	$ 11,778
Unsecured loan agreements, description	BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working capital purpose.
Balance due amount		$ 106,800	$ 100,200

Short-term Loan (Details)

Short-term Loan (Details) - USD ($)	Apr. 14, 2020	Feb. 18, 2020	Dec. 31, 2020
Maturity date	Apr. 13, 2022
Accrued interest expense			$ 1,302
Unsecured Loan Agreement [Member]
Unsecured loan amount		$ 100,000
Maturity date		Aug. 17, 2020
Interest rate		1.50%

Related Parties Transactions (D

Related Parties Transactions (Details)	12 Months Ended
	Dec. 31, 2020
BioFirst Corporation (the "BioFirst") [Member]
Relationship with the Company and its subsidiaries, description	Entity controlled by controlling beneficiary shareholder of Yuangene
BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)") [Member]
Relationship with the Company and its subsidiaries, description	100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the "Rgene") [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation (the "Yuangene") [Member]
Relationship with the Company and its subsidiaries, description	Controlling beneficiary shareholder of the Company
AsianGene Corporation [Member]
Relationship with the Company and its subsidiaries, description	Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Eugene Jiang [Member]
Relationship with the Company and its subsidiaries, description	Former President and Chairman
Keypoint Technology Ltd. (the "Keypoint') [Member]
Relationship with the Company and its subsidiaries, description	The Chairman of Keypoint is Eugene Jiang's mother.
Lion Arts Promotion Inc. (the "Lion Arts") [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company
Yoshinobu Odaira (the "Odaira") [Member]
Relationship with the Company and its subsidiaries, description	Director of the Company
Euro-Asia Investment & Finance Corp Ltd. (the "Euro-Asia") [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company
Kimho Consultants Co., Ltd. (the "Kimho") [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company
LBG USA, Inc. (the "LBG USA") [Member]
Relationship with the Company and its subsidiaries, description	100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the "LionGene") [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the "Jiangs") [Member]
Relationship with the Company and its subsidiaries, description	Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
GenePharm Inc. (the "GenePharm") [Member]
Relationship with the Company and its subsidiaries, description	Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.
Amkey Ventures, LLC ("Amkey") [Member]
Relationship with the Company and its subsidiaries, description	An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan [Member]
Relationship with the Company and its subsidiaries, description	Entity controlled by controlling beneficiary shareholder of ABVC

Related Parties Transactions _2

Related Parties Transactions (Details 1) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Accounts receivable due from related parties	$ 143,435	$ 143,278
GenePharm Inc. [Member]
Accounts receivable due from related parties	142,225	142,225
Rgene [Member]
Accounts receivable due from related parties		1,053
Amkey [Member]
Accounts receivable due from related parties	$ 1,210

Related Parties Transactions _3

Related Parties Transactions (Details 2) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total	$ 696,255	$ 333,682
Rgene [Member]
Total	42,911	36,332
AsiaGene [Member]
Total	4,241	3,578
BioFirst [Member]
Total		137,151
BioFirst (Australia) [Member]
Total	373,235	40,000
BioHopeKing Corporation [Member]
Total	123,583	115,946
LBG USA [Member]
Total	675	675
BioLite Japan [Member]
Total	150,000
Keypoint [Member]
Total	$ 1,610

Related Parties Transactions _4

Related Parties Transactions (Details 3) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total	$ 288,445	$ 425,689
LionGene Corporation [Member]
Total		10,275
BioFirst Corporation [Member]
Total	23,647	24,182
AsiaGene [Member]
Total		24,017
YuanGene [Member]
Total	9,205	9,205
The Jiangs [Member]
Total	16,627	40,031
Kimho [Member]
Total		21,500
Euro Asia [Member]
Total	0	12,000
Due to shareholders [Member]
Total	166,261	284,479
Due to employees [Member]
Total	$ 72,704

Related Parties Transactions _5

Related Parties Transactions (Details Textual) - USD ($)

Jul. 02, 2020

May 08, 2020

Apr. 14, 2020

Oct. 15, 2019

Aug. 02, 2019

Jul. 12, 2019

Jul. 02, 2019

May 12, 2019

Feb. 02, 2019

May 11, 2018

Sep. 25, 2017

Apr. 12, 2017

Oct. 31, 2020

Aug. 31, 2019

Jun. 30, 2019

May 27, 2019

Feb. 27, 2019

Jan. 20, 2019

Dec. 31, 2018

Nov. 30, 2018

Jun. 27, 2018

Jan. 18, 2018

Dec. 31, 2017

Sep. 30, 2017

Jan. 26, 2017

Sep. 30, 2019

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Aug. 08, 2018

Related Parties Transactions (Textual)

Principal amount

$ 124,400

Interest expenses

$ 405,032

$ 482,014

Loan maturity date

Apr. 13, 2022

Conversion price

$ 7

Conversion of debt

$ 4,872,340

Conversion of debt, shares

696,051

Related party transactions, description

Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $837,726 to 119,675 shares of the Company’s common stock at a conversion price of $7.00 per share.

Outstanding advance balance

$ 288,445

425,689

Keypoint Note [Member]

Related Parties Transactions (Textual)

Principal amount

$ 250,000

Interest rate percentage

8.00%

Note Holders [Member]

Related Parties Transactions (Textual)

Aggregated common shares

795,735

Employee Stock [Member]

Related Parties Transactions (Textual)

Advances bear interest, description

The Company had advances from one employee for working capital purpose. The outstanding balance due to this employee amounted to $72,704 as of December 31, 2020. This loan bears interest rate of 1.5% per annum, and is due on demand.

Kimho [Member]

Related Parties Transactions (Textual)

Related party transactions, description

The Company entered into an agreement with Kimho for consulting service, with such services to begin in September 2019. As of December 31, 2020 and 2019, the outstanding services charge was $0 and $21,500, respectively.

Outstanding advance balance

21,500

Outstanding services charge

52,000

21,500

BioFirst [Member]

Related Parties Transactions (Textual)

Principal amount

$ 150,000

Outstanding loan balance

0

128,683

Accrued interest

$ 0

8,468

Loan agreement, description

Bears interest at 1% per month (or equivalent to 12% per annum

Aggregate working capital

21,317

Stock purchase agreement, description

On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst.

Outstanding advance balance

$ 23,647

24,182

Rgene Corporation [Member]

Related Parties Transactions (Textual)

Principal amount

2,911

36,332

Outstanding loan balance

31,684

29,194

Accrued interest

$ 11,227

7,138

Loan agreement, description

The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019

Asiangene Corporation [Member]

Related Parties Transactions (Textual)

Outstanding loan balance

$ 0

3,343

Accrued interest

681

235

Aggregate working capital

0

$ 24,017

Amount of equivalent

$ 3,560

Interest rate percentage

0.00%

Outstanding advance balance

$ 24,017

Asiangene Corporation [Member] | NT [Member]

Related Parties Transactions (Textual)

Loan agreement, description

The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019.

Aggregate working capital

$ 100,000

BioFirst (Australia) [Member]

Related Parties Transactions (Textual)

Principal amount

$ 321,487

$ 150,000

$ 40,000

Outstanding loan balance

$ 373,235

40,000

Interest rate percentage

12.00%

12.00%

0.00%

12.00%

Loan maturity date

Jun. 30, 2021

Jul. 11, 2020

Other receivable from related parties

$ 123,583

115,946

Advances bear interest, description

The advances bear interest 1% per month

LBG USA, Inc.[Member]

Related Parties Transactions (Textual)

Loan agreement, description

The advances bear 0% interest rate and are due on demand.

Outstanding advance

$ 0

$ 675

675

$ 0

BioLite Taiwan [Member]

Related Parties Transactions (Textual)

Loan agreement, description

The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.

Aggregate working capital

$ 430,817

Interest rate percentage

0.00%

Other receivable from related parties

$ 0

$ 0

Conversion price

$ 7

Conversion of debt

$ 428,099

Conversion of debt, shares

61,157

BioLite Taiwan [Member] | NT [Member]

Related Parties Transactions (Textual)

Aggregate working capital

$ 13,295,000

BioFirst [Member]

Related Parties Transactions (Textual)

Outstanding loan balance

$ 160,871

Aggregate working capital

$ 625,646

$ 950,000

Interest rate percentage

12.00%

12.00%

12.00%

Loan maturity date

Feb. 1, 2020

May 27, 2020

Conversion price

$ 7

Conversion of debt

$ 625,646

Conversion of debt, shares

89,378

Stock purchase agreement, description

On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $693,000 to 99,000 shares of the Company’s common stock at a conversion price of $7.00 per share.

Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $160,000 to 22,858 shares of the Company’s common stock at a conversion price of $7.00 per share.

BioFirst [Member] | Conversion Agreements One [Member]

Related Parties Transactions (Textual)

Interest rate percentage

0.00%

Stock purchase agreement, description

On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $597,128 to 85,304 shares of the Company’s common stock at a conversion price of $7.00 per share.

BioFirst [Member] | NT [Member]

Related Parties Transactions (Textual)

Aggregate working capital

$ 19,430,000

BioLite BVI [Member]

Related Parties Transactions (Textual)

Aggregate working capital

$ 987,134

Interest rate percentage

12.00%

Loan maturity date

May 11, 2020

May 11, 2019

Stock purchase agreement, description

On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $987,134 to 141,020 shares of the Company’s common stock at a conversion price of $7.00 per share.

BioLite BVI [Member] | NT [Member]

Related Parties Transactions (Textual)

Aggregate working capital

$ 30,000,000

Everfront Biotech Inc. [Member]

Related Parties Transactions (Textual)

Investment and equity transfer agreement, description

Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $160,000 to 22,858 shares of the Company’s common stock at a conversion price of $7.00 per share.

YuanGene [Member]

Related Parties Transactions (Textual)

Aggregate working capital

$ 50,000

$ 9,205

9,205

Interest rate percentage

12.00%

Loan maturity date

Jan. 19, 2020

Jan. 19, 2019

Conversion price

$ 7

Conversion of debt

$ 50,000

Conversion of debt, shares

7,143

YuanGene [Member] | Conversion Agreements [Member]

Related Parties Transactions (Textual)

Aggregate working capital

$ 42,690

Interest rate percentage

0.00%

Conversion price

$ 7

Conversion of debt

$ 42,690

Conversion of debt, shares

6,099

Related party transactions, description

On August 1, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $42,690 to 6,099 shares of the Company’s common stock at a conversion price of $7.00 per share.

Jiangs [Member]

Related Parties Transactions (Textual)

Outstanding loan balance

2,488

Accrued interest

$ 5,947

154

Interest expenses

$ 0

1

Loan agreement, description

The advances bear 0% interest rate and are due on demand.

Aggregate working capital

$ 16,627

$ 40,031

Interest rate percentage

0.00%

0.00%

1.00%

Related party transactions, description

Since 2018, the Jiangs have advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreement to convert the remaining balance of $353,050 to 50,436 shares of the Company's common stock at a conversion price of $7.00 per share.

Lion Gene [Member]

Related Parties Transactions (Textual)

Outstanding loan balance

0

$ 10,020

Accrued interest

0

255

Interest expenses

$ 0

955

255

Lion Gene [Member] | NT [Member]

Related Parties Transactions (Textual)

Aggregate working capital

$ 300,000

Amount of equivalent

$ 10,020

Due to Shareholders [Member]

Related Parties Transactions (Textual)

Accrued interest

166,261

284,479

Interest expenses

21,520

14,910

Outstanding advance balance

166,261

284,479

Due to Shareholders [Member] | NT [Member]

Related Parties Transactions (Textual)

Loan agreement, description

The advances bear interest rate from 12% to 13.6224% per annum.

Amount of equivalent

$ 160,770

$ 160,770

Euro Asia [Member]

Related Parties Transactions (Textual)

Outstanding advance

12,000

Outstanding advance balance

0

12,000

BioLite Japan [Member]

Related Parties Transactions (Textual)

Loan agreement, description

The Company advanced an amount of $150,000 and the advance bear 0% interest rate.

Aggregate working capital

$ 150,000

Outstanding advance

$ 0

$ 0

Consulting Agreement [Member]

Related Parties Transactions (Textual)

Conversion price

$ 2.9

Aggregated common shares

521,887

Keypoint [Member]

Related Parties Transactions (Textual)

Principal amount

$ 1,610

Outstanding loan balance

$ 1,610

Interest rate percentage

6.50%

Loan maturity date

Oct. 30, 2021

Equity (Details)

Equity (Details)	1 Months Ended
	Aug. 31, 2019USD ($)shares
Amount of Debt Converted | $	$ 4,872,340
Number of Shares Issued | shares	696,051
Lion Arts Promotion Inc [Member]
Amount of Debt Converted | $	$ 97,864
Number of Shares Issued | shares	13,981
LionGene Corporation [Member]
Amount of Debt Converted | $	$ 428,099
Number of Shares Issued | shares	61,157
BioFirst Corporation [Member]
Amount of Debt Converted | $	$ 2,902,911
Number of Shares Issued | shares	414,702
YuanGene Corporation [Member]
Amount of Debt Converted | $	$ 92,690
Number of Shares Issued | shares	13,242
The Jiangs [Member]
Amount of Debt Converted | $	$ 1,190,776
Number of Shares Issued | shares	170,111
AsiaGene Corporation [Member]
Amount of Debt Converted | $	$ 160,000
Number of Shares Issued | shares	22,858

Equity (Details Textual)

Equity (Details Textual)

Jul. 08, 2020

May 03, 2019

May 03, 2019

Mar. 12, 2019

Feb. 08, 2019$ / sharesshares

Feb. 08, 2016shares

Nov. 21, 2020USD ($)shares

Aug. 31, 2019USD ($)$ / shares

Jun. 30, 2019USD ($)shares

Feb. 28, 2017

Oct. 02, 2016

Aug. 26, 2016USD ($)

May 06, 2016

Mar. 31, 2016

Mar. 21, 2016$ / sharesshares

Feb. 17, 2016shares

Oct. 31, 2015USD ($)

Dec. 31, 2020USD ($)Investor$ / sharesshares

Dec. 31, 2019USD ($)$ / sharesshares

Mar. 12, 2020$ / sharesshares

May 26, 2017USD ($)

Equity (Textual)

Common stock, authorized

360,000,000

100,000,000

100,000,000

Common stock, par value | $ / shares

$ 0.001

$ 0.001

$ 0.001

Due to related parties | $

$ 288,445

$ 425,689

Consulting fees | $

$ 4,514,800

Common stock, shares issued

24,420,526

19,478,168

Financial amendment, description

The Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority ("FINRA"). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company's common stock were exchanged for 17,693,625 shares of the Company's Common Stock. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.

Agreement, description

The Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company's Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company's Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).

The Company issued 1,468,750 shares ("Shares") of the Company's Common Stock, par value $0.001 (the "Offering") to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the "SPA"). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.

The Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company's first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.

Due to related parties consideration | $

$ 4,872,340

Common stock price per share | $ / shares

$ 7

Forward split ratio

The Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.

i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized common stock of the Company (the "Common Stock") and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes.

1 to 3.141

Subscription receivable | $

$ 350,000

Stock subscription receivable | $

$ 40,751,807

$ 28,180,348

Common Stock [Member]

Equity (Textual)

Issuance of common shares, shares

7,593,364

Capital contributions

3,384,615

Private Placement [Member]

Equity (Textual)

Aggregated capital contributions | $

$ 7,615,331

Purchase price per share | $ / shares

$ 2.25

Number of investors | Investor

45

Note Holders [Member]

Equity (Textual)

Aggregated common shares

795,735

2016 Equity Incentive Plan [Member]

Equity (Textual)

Common stock issued pre-stock split

50,000

Common stock issued post-stock split

157,050

Share Exchange Agreement [Member]

Equity (Textual)

Common stock issued pre-stock split

52,336,000

Common stock issued post-stock split

164,387,376

Share Exchange Agreement One [Member]

Equity (Textual)

Common stock issued pre-stock split

52,936,583

Common stock issued post-stock split

166,273,921

Share Exchange Agreement Two [Member]

Equity (Textual)

Common stock issued pre-stock split

51,945,225

Common stock issued post-stock split

163,159,952

Percentage of common shares issued and outstanding

79.70%

Percentage of issued share capital

100.00%

Share Exchange Agreement Three [Member]

Equity (Textual)

Common stock issued pre-stock split

52,936,583

Common stock issued post-stock split

166,273,921

Exchange ratio

0.2536-for-1

Share Exchange Agreement Four [Member]

Equity (Textual)

Common stock issued pre-stock split

65,431,144

Common stock issued post-stock split

205,519,223

Collaborative Arrangement [Member]

Equity (Textual)

Issuance of common shares | $

$ 3,000,000

Issuance of common shares, shares

428,571

Consulting agreement, description

The Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company's Common Stock at $1.00 per share for any amount exceeding $3,000.

Collaborative Arrangement One [Member]

Equity (Textual)

Due to related parties | $

$ 100,000,000

Percentage of payments under collaborative agreement

6.50%

Co-Dev Agreement [Member]

Equity (Textual)

Due to related parties | $

$ 3,000,000

Euro-Asia Investment & Finance Corp Ltd. [Member]

Equity (Textual)

Common stock, shares issued

644,972

Stock subscription receivable | $

$ 4,063,320

$ 3,160,360

BioKey [Member]

Equity (Textual)

Common stock issued post-stock split

1,642,291

Issuance of common shares, shares

29,561,231

Purchase price per share | $ / shares

$ 1.50

BioLite [Member]

Equity (Textual)

Issuance of common shares, shares

74,997,546

Articles of Incorporation [Member]

Equity (Textual)

Common stock, par value | $ / shares

$ 0.001

View Trade Securities Inc [Member]

Equity (Textual)

Consulting fees | $

$ 135,000

Common stock, shares issued

60,000

Placement agent agreement, description

The agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision.

Consulting Agreement [Member]

Equity (Textual)

Common stock price per share | $ / shares

$ 2.9

Aggregated common shares

521,887

Unrestricted common shares

50,000

Non Related Parties [Member]

Equity (Textual)

Debt conversion, description

a. Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company's common stock, and warrants to purchase 159,145 shares of the Company's common stock. b. The Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company's common stock, and warrants to purchase 154,368 shares of the Company's common stock. c. The C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company's common stock, and warrants to purchase 162,908 shares of the Company's common stock. d. The KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company's common stock, and warrants to purchase 126,530 shares of the Company's common stock. e. The Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company's common stock, and warrants to purchase 192,784 shares of the Company's common stock. f.The KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on April 5, 2020, in exchange for 120,121 shares of the Company’s common stock, and warrants to purchase 120,212 shares of the Company’s common stock.

Kameyama [Member]

Equity (Textual)

Issuance of common shares, shares

24,694

Unpaid consulting fees | $

$ 49,388

Maximum [Member] | Articles of Incorporation [Member]

Equity (Textual)

Common stock, authorized

100,000,000

Maximum [Member] | Consulting Agreement [Member]

Equity (Textual)

Purchase price per share | $ / shares

$ 3.68

Minimum [Member] | Articles of Incorporation [Member]

Equity (Textual)

Common stock, authorized

20,000,000

Minimum [Member] | Consulting Agreement [Member]

Equity (Textual)

Purchase price per share | $ / shares

$ 2

Stock Options (Details)

Stock Options (Details) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2020
Summary of assumptions used to estimate fair value of stock options granted
Risk free interest rate	0.38%
Expected term (in years)	5 years
Dividend yield	0.00%
Expected volatility	89.01%

Stock Options (Details 1)

Stock Options (Details 1) - USD ($)	Oct. 30, 2020	Dec. 31, 2020
Number of Underlying Shares
Granted	545,182
Outstanding as of December 31, 2020		545,182
Stock Options [Member]
Number of Underlying Shares
Outstanding as of January 1, 2020
Granted		545,182
Forfeited
Outstanding as of December 31, 2020		545,182
Exercisable as of December 31, 2020		545,182
Vested and expected to vest		545,182
Weighted-Average Exercise Price Per Share
Outstanding as of January 1, 2020
Granted		2
Forfeited
Outstanding as of December 31, 2020		2
Exercisable as of December 31, 2020		2
Vested and expected to vest		$ 2
Weighted-Average Contractual Life Remaining in Years
Granted		9 years 10 months 21 days
Outstanding as of December 31, 2020		9 years 10 months 21 days
Exercisable as of December 31, 2020		9 years 10 months 21 days
Vested and expected to vest		9 years 10 months 21 days
Aggregate Intrinsic Value
Granted		$ 616,056
Outstanding as of December 31, 2020		616,056
Exercisable as of December 31, 2020		616,056
Vested and expected to vest		$ 616,056

Stock Options (Details Textual)

Stock Options (Details Textual) - USD ($)	Oct. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Stock Options (Textual)
Stock options aggregate	545,182
Company granted stock option		545,182
Conversion price	$ 2
Exercise price		$ 2
Consulting fees	$ 1,090,361
Options vested grant date exercisable		10 years
Weighted average grant date fair value		$ 3.13
Stock-based compensation expense		$ 1,706,419	$ 0
2016 Equity Incentive Plan [Member]
Stock Options (Textual)
Options available for grant		2,812,949

Loss per Share (Details)

Loss per Share (Details) - Parent [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss attributable to ABVC's common stockholders	$ (9,791,164)	$ (3,641,776)
Weighted-average shares outstanding:
Weighted-average shares outstanding - Basic	19,715,559	17,498,543
Stock options
Weighted-average shares outstanding - Diluted	19,715,559	17,498,543
Loss per share
-Basic	$ (0.50)	$ (0.21)
-Diluted	$ (0.50)	$ (0.21)

Lease (Details)

Lease (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
ASSETS
Operating lease right-of-use assets	$ 1,772,747	$ 524,445
LIABILITIES
Operating lease liabilities (current)	316,178	304,248
Operating lease liabilities (noncurrent)	$ 1,456,567	$ 235,555

Lease (Details 1)

Lease (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease expenses	$ 337,282	$ 301,437
Cash paid for amounts included in the measurement of operating lease liabilities	$ 337,282	$ 301,437
Weighted average remaining lease term	3 years 29 days	3 years 29 days
Weighted average discount rate	0.55%	0.55%

Lease (Details 2)

Lease (Details 2)	Dec. 31, 2020USD ($)
Leases [Abstract]
2021	$ 324,788
2022	341,527
2023	358,431
2024	375,337
2025	338,676
Thereafter	56,916
Total future minimum lease payments, undiscounted	1,795,675
Less: Imputed interest	22,930
Present value of future minimum lease payments	$ 1,772,745

Lease (Details Textual)

Lease (Details Textual) - USD ($)	May 03, 2019	Mar. 12, 2019	Mar. 21, 2016	Dec. 31, 2020	Dec. 31, 2019
Lease (Textual)
Operating lease right-of-use assets				$ 1,772,747	$ 524,445
Current operating lease liabilities				316,178	304,248
Non-current operating lease liabilities				1,456,567	$ 235,555
Description of reverse stock split	The Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.	i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized common stock of the Company (the "Common Stock") and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes.	1 to 3.141
ASC 842 [Member]
Lease (Textual)
Operating lease right-of-use assets				577,830
Operating lease liabilities				598,937
Current operating lease liabilities				301,105
Non-current operating lease liabilities				297,832
Cumulative-effect adjustment of opening balance of accumulated deficit				$ (21,107)

Business Combination (Details)

Business Combination (Details)	Feb. 08, 2019USD ($)
Purchase consideration:
Common Stock	$ 44,341,847	[1]
Allocation of the purchase price:
Cash and cash equivalents	531,147
Accounts receivable, net	188,550
Property and equipment, net	56,075
Operating lease right-of-use assets	485,684
Security deposits	10,440
Total assets acquired	1,271,896
Accounts payable	(56,204)
Accrued expenses and other current liabilities	(251,335)
Operating lease liability	(267,256)
Tenant security deposit	(2,880)
Total liabilities assumed	(577,675)
Total net assets acquired	694,221
Goodwill as a result of the Merger	$ 43,647,626
[1]	29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.

Business Combination (Details T

Business Combination (Details Textual)	Feb. 08, 2019USD ($)$ / sharesshares
Business Combination (Textual)
Goodwill write-down value | $	$ 43,647,626
Percentage of goodwill	100.00%
BioKey [Member]
Business Combination (Textual)
Common stock issued	29,561,231
Reverse stock split	1,642,291
Common stock per share | $ / shares	$ 1.50

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Feb. 07, 2021	Jan. 29, 2021
Subsequent Events (Texual)
Loan amount received	$ 104,167	$ 132,331
Maturity date	Feb. 6, 2026	Jan. 28, 2026
Bear interest rate	1.00%	1.00%